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CHAPTER 1 INTRODUCTION
Parts of this chapter has been published in Current Protein and Peptide Science

1.1 THE SUMO PATHWAY
The small ubiquitin-related modifiers (SUMOs) are small proteins that are reversibly
conjugated to hundreds of different proteins and therefore regulate many cellular processes
including cell cycle, nucleocytoplasmic transport, DNA repair, gene expression, and protein
stability. Currently, the fundamental molecular mechanisms for SUMO conjugation and
deconjugation have been relatively well established. At the same time, not only many SUMO
substrates have been identified but also the effects of SUMOylation on these substrates have been
elucidated in multiple model systems and organisms, including budding yeast, fission yeast,
mammalian culture cells, Xenopus and Arabidopsis.

1.1.1 SUMO as a post-translational modifier:
Although a single SUMO protein is expressed in yeast and invertebrates, vertebrates
express three SUMO proteins: SUMO-1, SUMO-2 and SUMO-3 (Geiss-Friedlander and Melchior,
2007). In human, SUMO-2 and SUMO-3 are ~96% homologous to other and are thus denoted as
SUMO-2/3, whereas the identity between SUMO-2/3 and SUMO-1 is less than 45%. All SUMOs
are expressed as the SUMO precursor proteins that must be post-translationally processed to
expose their C-terminal double-glycine (GG) motifs to generate the mature SUMOs for their
conjugation to protein targets (Dasso, 2008; Geiss-Friedlander and Melchior, 2007; Johnson,
2004). This processing step is catalyzed by the SUMO isopeptidases, called ubiquitin like protein
proteases (Ulps) in yeast (Li and Hochstrasser, 1999) and Sentrin-specific proteases (SENPs) in
vertebrates (Gong et al., 2000). Like ubiquitination, SUMOylation requires a similar enzymatic
cascade that involves three classes of enzymes. In the first step, which is ATP driven, the SUMO

2

E1 activating enzyme (Aos1-Uba2) activates the mature SUMO when a thioester bond is formed
between the C-terminal glycine residue of SUMO and the cysteine (C) residue of the E1 enzyme
(Figure 1.1) (Johnson et al., 1997). The second step involves the transfer of SUMO from E1 to the
catalytic cysteine (C) residue of the SUMO E2 conjugating enzyme (Ubc9) (Figure 1.1) (Johnson
and Blobel, 1997; Lee et al., 1998). The last step is the transfer of SUMO from Ubc9 to the target
protein where an isopeptide bond is formed between the C-terminal glycine residue (G) of SUMO
and a lysine (K) residue of the target (Figure 1.1). This is usually facilitated by an E3 ligase that
promotes SUMO conjugation to specific proteins (Figure 1.1) (Johnson, 2004; Melchior et al.,
2003). SUMO isopeptidases (SENPs) catalyze the reverse process of deconjugating SUMO from
the substrate.

Figure 1.1. The SUMO pathway. The precursor SUMO is processed by SUMO isopeptidases to generate the mature
SUMO exposing the terminal di-glycine motif. The mature SUMO is first activated and then conjugated to the
substrate by means of three enzymes E1 activating enzyme, E2 conjugating enzyme and E3 ligases. This dynamic
modification is reversible, where SENPs deconjugate SUMOs from the substrates.

1.1.2 SUMO consensus sequence:
Many SUMO substrates contain the SUMOylation consensus sequence Ψ-K-x-[E/D],
where Ψ is a hydrophobic amino acid residue, K is the lysine residue for SUMO conjugation, x is
any amino acid, and E/D represents either a glutamic acid (E) or an aspartic acid (D). This motif
is recognized by Ubc9, unlike the E2 conjugating enzymes for ubiquitination (Bernier-Villamor et
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al., 2002; Sampson et al., 2001). Interestingly, recent studies have shown that some SUMOylation
sites contain an inverted SUMOylation consensus sequence [E/D]-x-K-Ψ (Matic et al., 2010). In
many cases, the SUMOylation consensus sequence Ψ-K-x-[E/D] also contains an adjacent motif
to enhance its SUMO conjugation. The extended SUMOylation consensus sequence motifs include
the negatively charged amino acid-dependent SUMOylation motif (NDSM) with extra negatively
charged amino acids in close proximity to its core SUMOylation consensus sequence, the
hydrophobic cluster SUMOylation motif (HCSM) with a cluster of hydrophobic amino acids, and
the phosphorylation-dependent SUMOylation motif (PDSM) with an adjacent serine (S) residue
for phosphorylation (Blomster et al., 2009; Matic et al., 2010). On the other hand, many SUMO
conjugations occur at the non-consensus sequences, whereas many non-SUMOylated proteins also
contain the SUMOylation consensus sequences. Therefore, SUMOylation sites must be directly
determined and confirmed by in vitro and/or in vivo experiments.

1.1.3 SUMO E3 ligases:
Although SUMO E1 enzyme and Ubc9 alone are sufficient for in vitro SUMO modification
of many known substrates, SUMO E3 ligases play an important regulatory role in vivo by
increasing the SUMOylation efficiency and also by determining the substrate specificity. Based
upon their evolutionary conservation, the current known SUMO E3 ligases can be classified into
two main groups. A conservative group of E3 ligases has been found in all eukaryotes and contains
a RING-finger like domain called SP-RING domain, which is responsible for recruiting Ubc9
(Geiss-Friedlander and Melchior, 2007; Johnson, 2004; Yunus and Lima, 2009). The SP-RING
E3 ligases include the PIAS (protein inhibitor of activated STAT) family proteins (PIAS1, PIAS3,
PIASxα, PIASxβ and PIASy) in vertebrates and the Siz family proteins (Siz1 and Siz2) in
Saccharomyces cerevisiae (Dasso, 2008; Johnson, 2004; Melchior et al., 2003). The Siz1 and Siz2
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are required for most SUMO conjugation in budding yeast (Johnson and Gupta, 2001; Takahashi
et al., 2001). In yeast and human, the SUMO E3 ligase Mms21 also contains a SP-RING domain
and plays an essential role in DNA repair (Johnson and Gupta, 2001; Potts and Yu, 2005).
Furthermore, the yeast SP-RING E3 ligase Zip3 regulates the assembly of synaptonemal complex
during meiosis (Cheng et al., 2006a). On the other hand, the human PIAS-like E3 ligase hZimp10
is capable to stimulate the SUMOylation of androgen receptor (AR), leading to an increase of
transcription activity of AR (Sharma et al., 2003). In contrast to the conservative group of SPRING E3 ligases, the non-conservative group of E3 ligases is vertebrate-specific and has no
obvious yeast homologues. These vertebrate-specific E3 ligases include the nucleoporin
Nup358/RanBP2 (Pichler et al., 2002), the polycomb-group protein Pc2 (Kagey et al., 2003), the
histone deacetylases including HDAC4 (Zhao et al., 2005) and HDAC7 (Gao et al., 2008), and the
topoisomerase I-binding protein Topors (Pungaliya et al., 2007; Weger et al., 2005).

1.1.4 SUMO isopeptidases:
DeSUMOylation is essential to ensure the reversible nature of SUMO conjugation (Hay,
2007; Mukhopadhyay and Dasso, 2007). SUMO isopeptidases (Ulps/SENPs) are responsible for
both processing the SUMO precursors and deconjugating the SUMOs from their protein targets
(Figure 1.1) (Mukhopadhyay and Dasso, 2007). Budding yeast has two SUMO isopeptidases (Ulp1
and Ulp2/Smt4). While Ulp1 is associated with the nuclear pore complex (NPC) (Panse et al.,
2003), Ulp2 has a distribution throughout the nucleus (Li and Hochstrasser, 2000). Ulp1 is
responsible for processing the SUMO precursors and also essential for the cell cycle progression
through the G2/M phase (Li and Hochstrasser, 1999). Although Ulp2 is not essential for vegetative
growth, it is crucial for meiosis (Li and Hochstrasser, 2000). During mitosis, the Ulp2 is
preferentially required for sister chromatid cohesion at centromere regions, and the defects in Ulp2
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leads to the precocious loss of centromeric cohesion (Bachant et al., 2002). Interestingly, Ulp2 is
also specifically required for disassembly of polymeric SUMO chains (Bylebyl et al., 2003). The
distinct subcellular localizations of Ulp1 and Ulp2 are important to determine their substrate
specificities (Li and Hochstrasser, 2003). On the other hand, there are six different isopeptidases
(SENP1, SENP2, SENP3, SENP5, SENP6, and SENP7) in human cells. The six SENPs share a
common C-terminal catalytic domain but have distinct N-terminal domains, which are critical for
their subcellular localizations and substrate specificities (Hay, 2007; Mukhopadhyay and Dasso,
2007). The sequence alignment of the human SENPs and the budding yeast Ulps suggests that
SENP1, 2, 3 and 5 belong to the Ulp1-like branch, whereas SENP6 and 7 fall into the Ulp2-like
branch (Mukhopadhyay and Dasso, 2007). SENP1 and SENP2 are most closely related to each
other and catalyze both processing and deconjugation of SUMO-1 and SUMO-2/3 (Shen et al.,
2006a). In addition, both SENP1 and SENP2 are associated with the nuclear pore complex (NPC)
and have a distribution throughout the nucleus (Bailey and O'Hare, 2004; Hang and Dasso, 2002).
Among the six SENPs, SENP3 and SENP5 are most closely related with each other and localize
to the nucleolus with a preference for SUMO-2/3 processing and deconjugation (Yun et al., 2008).
Similar to Ulp2, SENP6 and SENP7 localize throughout the nucleoplasm and have a strong
preference for disassembly of SUMO-2/3 polymeric chains (Lima and Reverter, 2008). The
different sub-cellular localization of SUMO isopeptidases may determine their accessibilities to
discrete SUMO targets and therefore their substrate specificities.

1.2 HISTORY OF SUMO
About two decades ago, SUMO-1 modification was originally identified in mammalian
cells while investigating nuclear transport. Ran-GTPase-activating protein RanGAP1 is the first
discovered SUMO-1 substrate (Matunis et al., 1996). RanGAP1 hydrolysis Ran from its GTP
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bound state to GDP bound state; whereas RCC1 which is mostly localized to the nucleus converts
RanGDP to RanGTP. This results in a concentration gradient of RanGTP between the nucleus and
cytosol which is important for nuclear-cytoplasmic transport. Unmodified RanGAP1 was found
in the cytosol whereas the SUMO-1 modified form was found localized to the cytoplasmic fibers
of the nuclear pore complex (Mahajan et al., 1998) where it forms a complex with Ran Binding
Protein 2 (RanBP2) (Mahajan et al., 1997) and Ubc9. RanGAP1 is SUMO modified at a conserved
lysine residue towards the C-terminus of the protein (Mahajan et al., 1998).

1.3 THE KNOWN FUNCTIONS OF SUMO MODIFICATION
1.3.1 Regulation of protein-protein interaction
SUMO modification on a protein can either enhance (Figure 1.2A) or disrupt its contact
with an interacting partner. Here are a few examples where SUMO modification promotes proteinprotein interaction (i) SUMO modified PCNA recruits the helicase Srs2 (Pfander et al., 2005), (ii)
SUMO modification of Promyelocytic leukemia (PML) recruits several other proteins and is
important for the formation of PML nuclear bodies (Shen et al., 2006b), (iii) SUMO-modified Elk2
(transcription factor) localizes HDAC2. This is possible because of the non-covalent contact
between the SUMO on the modified protein and the SUMO Interacting Motif (SIM) on its
interacting partner (Minty et al., 2000). SIMs generally have a hydrophobic stretch (V/I-X-V/IV/I) which neighbors either a few acidic residues or phosphorylated serine/threonine residues. It
has also been shown that non-covalent interactions occur between these negatively charged
residues on SIM and the basic residues on SUMO (Lys39 in SUMO-1 and Lys 35 in SUMO-2).
The SIMs form a β strand which interacts either in parallel or anti-parallel orientation to the β2
strand on SUMO (Hecker et al., 2006). Sometimes SIMs exhibit paralogue specific binding; one
such example is DAXX. DAXX is a transcriptional co-repressor that binds to different SUMO-
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modified transcription factors near the promoter region (Chang et al., 2011). The hydrophobic
residues in the SIM in DAXX are flanked by serine residues which gets phosphorylated facilitating
binding to SUMO-1 and not to SUMO-2/3 (Chang et al., 2011).

1.3.2 Affects protein stability
SUMO modification of proteins has been shown to either stimulate (Figure 1.2B) or
antagonize ubiquitin-mediated degradation indirectly. Examples for the former are PML and
CENP-I (Mukhopadhyay et al., 2010; Tatham et al., 2008). In the presence of Arsenic trioxide,
PML gets polymeric SUMO-2/3 modified. RNF4 which is a SUMO targeted ubiquitin E3 ligase
(STUbL) has four SIMs in close proximity that recognize the polymeric SUMO-2/3 chains on
PML and gets recruited. This leads to poly ubiquitin moieties being added on PML thereby leading
to its degradation via the 26S proteasome (Tatham et al., 2008). In certain other cases like CDK6
and IκBα, SUMOylation can act as an inhibitor of ubiquitination. IκBα, inhibitor of NF-κB, retains
it to the cytosol. IκBα can get both ubiquitinated and SUMOylated at the same lysine residue.
SUMO modification of IκBα prevents its ubiquitination leading to the stabilization of the protein.
Stable IκBα retains NF-κB to the cytosol thereby inhibiting the transcription of its downstream
genes (Desterro et al., 1998).

1.3.3 Modulates enzyme activity
In some cases, SUMO modification of an enzyme can regulate the activity of the enzyme
(Figure 1.2C). Thymine DNA Glycosylase (TDG) is a DNA mismatch repair enzyme and a bona
fide SUMO target. When a G-U or G-A mismatch occurs, TDG binds to this site and removes the
mutated base. TDG has high affinity to this site and SUMO modification of TDG is required to
bring about a conformation change, so that it can be released from the site. Once released, SENPs
quickly remove SUMO from the enzyme, so that it can bind to another mismatched site (Hardeland
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et al., 2002). This is yet another example of SUMOylation being a highly dynamic process as the
deconjugation takes place rapidly when compared to the entire reaction cycle.

A

B

C

Figure 1.2. Functions of SUMO-modified targets. SUMO modification of a substrate can modulate the protein in
one or more ways. (A) SUMO-modification of a protein might increase the binding site for interaction. (B) Poly
SUMO-2/3 modification recruits RNF4 (Ubiquitin E3 ligase) via its SIM leading to ubiquitination and degradation
via the proteasome. (C) In certain other cases, SUMO modification regulate the enzyme activity.

1.4 ROLES OF SUMOYLATION IN REGULATION OF
BIOLOGICAL PROCESSES
1.4.1 DNA replication and repair:
Each cell takes the responsibility of maintaining its own genome. When the genome
integrity is altered, the cell has to quickly repair the damage which will otherwise affect gene
expression leading to adverse effects. SUMOylation and other post translational modifications can
reversibly change the localization, stability and other properties of DNA repair enzymes which
regulate the DNA repair pathways. Some of the DNA repair proteins modified by SUMO are
PCNA (Hoege et al., 2002), Rad52 (Sacher et al., 2006), Thymine DNA Glycosylase (TDG)

9

(Hardeland et al., 2002), XRCC4 (Yurchenko et al., 2006), Ku70 (Zhao and Blobel, 2005), BLM
(Eladad et al., 2005).
Proliferative Cell Nuclear Antigen (PCNA) is a homotrimeric clamp that surrounds DNA
acting as a scaffold to localize proteins involved in DNA replication and repair. PCNA is modified
by SUMO at two lysine residues (Lys 164 and to a lesser extent Lys 127) during S phase.
Conjugation to Lys 164 results in the recruitment of Srs2 (helicase-like enzyme). This displaces
Rad51, a recombinase, from the chromatin preventing undesirable recombination between sister
chromatids during S phase (Pfander et al., 2005). SUMO modification of PCNA at Lys 127
prevents the binding of Eco1, a protein required for sister chromatid cohesion. The authors
speculate that this modification is probably required to keep certain heavily transcribed regions
free of cohesion (Moldovan et al., 2006).
Rad52 is a protein involved in the repair of DNA double strand breaks through homologous
recombination by binding to single stranded DNA ends. During double strand breaks, Rad52 gets
SUMO modified and this leads to protection from ubiquitin mediated proteasomal degradation
probably by isolating Rad52 into DNA repair foci (Sacher et al., 2006).

1.4.2 Transcription:
Gene expression is initiated after transcription factors binds to the promoters which then
recruits chromatin remodelers, transcription activators or repressors. Many of the SUMO targets
are transcription factors. Although there are examples of SUMOylation leading to transcription
activation, it is generally associated with transcription repression (Gill, 2004). SUMO modification
of heat shock transcription factors HSF1 and HSF2 results in transcription activation. Conjugation
of SUMO to these proteins results in enhanced DNA binding. It has been shown that SUMO
deficient mutant of HSF1 leads to decreased transcription of its downstream genes (Goodson et
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al., 2001; Hong et al., 2001). There are also reports showing that SUMO modification of p53 and
Nuclear Factor of Activated T-cells (NFAT) results in transcriptional activation (Gostissa et al.,
1999; Rodriguez et al., 1999; Terui et al., 2004).
SUMO modification leading to transcription repression can be brought about by one or
both of the following mechanisms. In both cases SUMO modification may only be required for a
short period of time resulting in repressed chromatin state. Transcription factors that are
conjugated to SUMO can recruit chromatin remodelers with repressive activity (Figure 1.3) (Hay,
2005). Protein300 (p300) and Elk1 are both transcription regulators that can be SUMO modified.
p300 can be SUMO modified at two sites in tandem that recruits HDAC6 leading to transcription
repression (Girdwood et al., 2003). Similarly, SUMO modified Elk1 recruits HDAC2, which is
again a corepressor complex (Yang and Sharrocks, 2004). Histone H4 is another bona fide SUMO
target that localizes HDAC1 and Heterochromatin Protein 1- γ (HP1-γ) (Shiio and Eisenman,
2003). In all these cases, SUMO modification of transcription factors localizes repressor
complexes to the promoters leading to transcription repression of downstream genes.

Figure 1.3. SUMO modification plays a role in transcription repression. Many SUMO substrates are transcription
factors. SUMOylation of a transcription factor can recruit a repressor protein leading to transcription repression of the
downstream genes.

In certain other cases, SUMO modification of transcription factors can localize them to a
repressive nuclear domain. Polycomb group (PcG) bodies are known for transcription repression
and one of its component is SOP-2. SOP-2 can be SUMO modified, which is required for its
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recruitment to the PcG nuclear bodies. It has been shown that SUMO modification of SOP-2 leads
to transcriptional repression of Hox genes (Zhang et al., 2004). Various SUMO isopeptidases
remove SUMO from these transcription factors to derepress transcription (Girdwood et al., 2003).

1.4.3 Nuclear transport:
One of the major cellular processes that SUMOylation plays a role is in the regulation of
proteins in nucleo-cytoplasmic transport. In addition to SUMO-1 modification of RanGAP1
translocating it to the nuclear pore complex, SUMO modification affects the nuclear localization
of several substrates including p53, PTEN, CtBP.
p53 is a transcription factor that can be both SUMOylated and ubiquitinated (Rodriguez et
al., 1999). MDM2 is the ubiquitin E3 ligase responsible for the ubiquitination of p53 (Haupt et al.,
1997). Depending on MDM2 levels, p53 can either be mono or polyubiquitinated.
Monoubiquitination of p53 (i) results in exposing the nuclear export signal ensuing the cytoplasmic
localization of p53 and (ii) promotes its SUMO modification by PIASy (Carter et al., 2007). In
addition to this model, another theory proposes that SUMO-1 modification of p53 at NPC disrupts
its interaction with CRM1 (nuclear export receptor) thereby releasing the cargo in the cytoplasm
(Santiago et al., 2013). Polyubiquitination of p53 leads to its degradation via the 26S proteasome
(Kubbutat et al., 1997).
PTEN which is a tumor suppressor has a well characterized role as a phosphatase in the
PI3K-AKT pathway in the cytosol (Cantley and Neel, 1999). In addition, PTEN also has important
functions in the nucleus including apoptosis and chromosome stability (Planchon et al., 2008).
SUMO modification of PTEN has been shown to play an important part in the nucleo-cytoplasmic
shuttling. PTEN gets SUMO modified at two lysine residues K254 and K266. SUMOylation at
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residue 266 results in the retention of PTEN near the plasma membrane, however K254
SUMOylation retains PTEN in the nucleus (Huang et al., 2012).
C-terminal Binding Protein (CtBP) functions as a transcriptional corepressor and has been
identified as a SUMO target. SUMO modification of CtBP grips it in the nucleus and the SUMO
deficient mutant of CtBP has cytoplasmic localization (Lin et al., 2003).

1.4.4 Cell cycle progression through mitosis:
1.4.4.1 SUMO signals at centromere and kinetochores:
The subcellular localization of SUMO at mitotic centromeres and kinetochores has been
extensively analyzed by fluorescence microscopy in different organisms including human,
Xenopus and Drosophila (Azuma et al., 2005; Nie et al., 2009; Zhang et al., 2008) (Figure 1.4).
The mitotic centromere and kinetochore can be structurally divided into four distinct regions
including inner centromere, inner kinetochore, outer kinetochore and fibrous corona (McEwen and
Dong, 2010) (Figure 1.4). Here we briefly summarize the key findings about the SUMO signals at
centromeres and kinetochores during mitosis (Azuma et al., 2005; Nie et al., 2009; Zhang et al.,
2008) (Figure 1.4). 1) Immunofluorescence microscopy analysis using antibodies specific to
SUMO-2/3 showed that SUMO-2/3 signals are concentrated to many distinct foci on the
condensed chromosomes from prophase to metaphase and eventually coat the entire chromosomes
during anaphase and telophase in mammalian cells (Zhang et al., 2008). During metaphase, the
SUMO-2/3 foci on the chromosomes are significantly co-localized with the inner centromere
protein CENP-B and partially overlapped with the inner kinetochore protein CENP-C (Zhang et
al., 2008) (Figure 1.4). In contrast, the SUMO-1 signals are localized to the mitotic spindle during
metaphase and later concentrated to the spindle midzone during anaphase and telophase (Zhang et
al., 2008). These results support a model that SUMO-1 and SUMO-2/3 paralogs are conjugated to
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different subsets of proteins at distinct subcellular localizations and therefore regulate discrete
mitotic processes in vertebrates (Zhang et al., 2008). 2) In Xenopus egg extracts, the EGFPSUMO-2 signals are co-localized with Aurora B at inner centromeres of condensed chromosomes
(Azuma et al., 2005) (Figure 1.4). It has been shown that in the mitotic Xenopus egg extracts,
topoisomerase IIα (Topo IIα) localized to the inner centromere region, is the major SUMO-2/3
substrate (Azuma et al., 2005; Azuma et al., 2003). 3) In Drosophila cultured cells, SUMO
conjugates are mainly localized to inner centromeres and outer kinetochore plates during
prometaphase and are also targeted to the spindle midzone during anaphase. This result suggests
that the single SUMO in invertebrates, such as Drosophila, plays the roles of both vertebrate
SUMO-1 and SUMO-2/3 during mitosis (Nie et al., 2009) (Figure 1.4). In all the above organisms
ranging from invertebrates to mammals, the SUMO signals have been observed at centromeres
and kinetochores during the early stages of mitosis including prophase, prometaphase and
metaphase (Figure 1.4).
Three types of posttranslational modifications, including phosphorylation, ubiquitination
and SUMOylation, have been demonstrated to play the essential roles in chromosome segregation
during mitosis (Dasso, 2008). Interestingly, only “SUMOylation” signals have been reported to be
directly detected at mitotic centromeres and kinetochores in both invertebrate and vertebrate cells
(Azuma et al., 2005; Nie et al., 2009; Zhang et al., 2008) (Figure 1.4). These evolutionally
conserved “SUMOylation” signals at mitotic centromeres and kinetochores are consistent with a
model that SUMOylation functions as a master regulator of centromere and kinetochore activities
during mitosis.
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Figure 1.4. Both SUMO signals and known SUMO substrates are associated with the mitotic centromere and
kinetochore of a condensed chromosome. The enlarged region of the mitotic chromosome represents inner
centromere, inner kinetochore, outer kinetochore, and fibrous corona. The exact localizations of SUMO signals at
centromeres and kinetochores in human HeLa cells, Xenopus egg extracts and Drosophila culture cells are determined
by fluorescence or immunofluorescence microscopy (on the left). The known vertebrate SUMO targets, which have
been identified and confirmed in vivo, are schematically represented here (on the right) and also described in Table
1.1.

Although the “SUMOylation” signals have not been directly detected in yeast, many centromere
and kinetochore proteins have been identified as SUMO substrates in yeast, supporting a conserved
role of SUMOylation in regulation of mitosis in all eukaryotes (Dasso, 2008). Consistent with the
conserved role of SUMOylation in regulation of the centromere/kinetochore activities, SUMOs
have been identified as suppressors of the temperature-sensitive mutants of the centromeric protein
CENP-C in both yeast and chicken cells by genetic screenings (Fukagawa et al., 2001; Meluh and
Koshland, 1995).
1.4.4.2 Role of SUMO modification at centromeres and kinetochores:
Consistent with the observed SUMO signals at centromeres and kinetochores in both
invertebrates and vertebrates (Figure 1.4), many centromere and kinetochore proteins have been
identified as SUMO targets in yeast and vertebrates [8]. Some of the vertebrate SUMO targets
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associated with centromeres and kinetochores and also the roles of their SUMOylation in control
of chromosome segregation will be discussed. The precise localizations of these vertebrate SUMO
targets at the centromere and kinetochore region are elucidated in Figure 1.4 and Table 1.1.
Furthermore, the other information and properties of these SUMO targets, including their protein
GI numbers, SUMOylation sites, SUMO-1 or SUMO-2/3-preferential modification, SUMOylation
time during the cell cycle, associated protein complexes, and corresponding reference(s), are
summarized in Table 1.1.


Topoisomerase IIα
Topoisomerase IIα (Topo IIα) has been identified as one of the first mitotic SUMO targets

in budding yeast and vertebrates (Table 1.1 and Figure 1.4) (Azuma et al., 2003; Bachant et al.,
2002). During mitosis, Topo IIα is re-localized from chromosome arms to the centromeres of
sister-chromatids (Christensen et al., 2002; Tavormina et al., 2002). One of the main functions of
Topo IIα at the centromere is to decatenate the last major site of attachment between sister
chromatids for chromosome segregation (Lee and Bachant, 2009). Accumulating evidence has
indicated that SUMOylation plays a critical role in regulation of Topo IIα-mediated decatenation
of centromeric DNA during mitosis (Ryu et al., 2010). PIASy has been found to be required for
SUMO-2/3 modification of Topo IIα and also the accumulation of SUMO-2/3 conjugates at the
inner centromere region of mitotic chromosomes in Xenopus extracts (Figure 1.4) (Azuma et al.,
2005).
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Table1.1. The known SUMO targets at centromeres and kinetochores in vertebrates
SUMO
Locations
Targets

Aurora B

Organisms
(GI
number)

Human

SUMOylation
Sites

SUMO-1
or SUMO2/3

Borealin

Topo IIα

Human

In Protein

Time

Complexes

Ref.

SUMO-2/3

CPC

(Klein et
al., 2009)

None

(Azuma et
al., 2003;
Ryu et al.,
2010)

Mitosis

Early
Unknown

SUMO-2/3

(8922438)

Mitosis

Xenopus

Early

(14822280
6)

CPC

(Ban et al.,
2011;
FernandezMiranda et
al., 2010)

Early
K202

(83776600)
Centromer
e

SUMOylation

K660

SUMO-2/3
Mitosis

Unknown

SUMO-2/3

S Phase

CENP-H/I/K

(Mukhopad
hyay et al.,
2010)

Unknown

SUMO-2/3

S Phase

CENP-H/I/K

(Mukhopad
hyay et al.,
2010)

Unknown

SUMO-2/3

Unknown

Ndc80/Hec1

(Zhang et
al., 2008)

None

(Yang et
al., 2011;
Zhang et
al., 2008)

None

(Zhang et
al., 2008)

RRSU

(Joseph et
al., 2004;
Mahajan et
al., 1997;
Mahajan et
al., 1998;
Matunis et
al., 1996;
Matunis et
al., 1998)

Human
Inner
Kinetocho
re

CENP-H
(12597655)
Human
CENP-I
(41352697)
Human

Outer
Kinetocho
re

Nuf2

(11796842
0)
Human

Late
K250

BubR1

SUMO-2/3

(59814247)

Mitosis

Human
Unknown

CENP-E

SUMO-2/3

Unknown

(71061468)
Fibrous
Corona
Mouse
RanGAP1

(34194180
6)

K526

SUMO-1

Constitutive
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Note: K stands for a lysine residue. Ref. represents the corresponding reference(s) for each SUMO target.
The RRSU complex consists of RanBP2/Nup358, RanGAP1-SUMO1 and Ubc9. The chromosomal
passenger complex (CPC) contains Aurora B kinase, INCENP, Survivin and Borealin.

Recent studies by Ryu and Azuma have shown that the N-terminus of PIASy is responsible
for the kinetochore localization of PIASy by interacting with Rod and Zw10, components of the
RZZ complex at the kinetochore fibrous corona (Ryu and Azuma, 2010). Furthermore, the
kinetochore localization of PIASy is essential for the centromeric SUMO-2/3 modification of Topo
IIα and other chromosome-associated proteins during mitosis (Ryu and Azuma, 2010).
Interestingly, PIASy-dependent SUMO-2/3 modification of Topo IIα significantly inhibits the
decatenation activity of Topo IIα in Xenopus egg extracts (Ryu et al., 2010). Furthermore, Topo
IIα is modified by SUMO-2/3 at the lysine 660 (K660) within the DNA gate domain involved in
the DNA cleavage and re-ligation. The SUMO-2/3 modification of Topo IIα at the K660 is
responsible for SUMOylation- mediated inhibition of Topo IIα, supporting a model that PIASydependent SUMOylation of Topo IIα functions in temporally preventing the resolution of
centromeric DNA until the onset of anaphase (Ryu et al., 2010).


The chromosome passenger complex at inner centromere
The chromosomal passenger complex (CPC) consists of the Aurora B kinase and three

non-enzymatic subunits INCENP, Survivin and Borealin (Ruchaud et al., 2007). The CPC has a
dynamic localization during mitosis. At the entry of mitosis, the CPC is initially localized to both
chromosome arms and inner centromeres (Figure 1.4).

As the cell cycle progresses to

prometaphase and metaphase, the CPC is mainly concentrated to the inner centromeres. Upon the
sister-chromatid separation at the onset of anaphase, the CPC is re-localized from the inner
centromeres to the spindle midzone (Ruchaud et al., 2007). The CPC plays a central role in
correcting erroneous kinetochore-microtubule attachments during prometaphase, SAC, and
cytokinesis (Carmena and Earnshaw, 2003; Ruchaud et al., 2007).
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Recent studies have revealed that the human Aurora B kinase is preferentially modified by
SUMO-2/3 at lysine 202 (K202) within its kinase domain (Table 1.1 and Figure 1.4) (Ban et al.,
2011; Fernandez-Miranda et al., 2010). As the major SUMOylation site of human Aurora B, the
K202 is located within a highly conserved sequence region (IHRDIKPEN), which is identical
among the Aurora B proteins of different species ranging from yeast to human and also contains
the SUMOylation consensus motif (IKPE) (Ban et al., 2011; Fernandez-Miranda et al., 2010).
PIAS3 efficiently stimulates the SUMO-2/3-specific modification of Aurora B in vivo (Ban et al.,
2011). Consistent with the PIAS3-specific stimulation of Aurora B SUMOylation, the GFP-tagged
PIAS3 proteins have been found to be associated with kinetochores as paired foci on both sides of
Aurora B during prophase and prometaphase (Ban et al., 2011). The authors then showed that in
HeLa cells, deSUMOylation of Aurora B occurs only by overexpression of FLAG-SENP2 but not
by any of the other FLAG-tagged mammalian SENPs (SENP1, SENP2, SENP5 and mouse SENP2
isotype Smt3IP2/Axam2), (Ban et al., 2011). Consistent with the previous finding (Zhang et al.,
2008), overexpression of FLAG-SENP2 does not affect Aurora B localization to inner centromeres
during mitosis, indicating that SUMO-2/3 modification of Aurora B is not required for its
localization to inner centromeres (Ban et al., 2011). Moreover, it has been shown recently that
SUMO-2/3 modification of Aurora B can greatly enhance its autophosphorylation in vivo, which
is essential for its activation during mitosis (Ban et al., 2011). This result supports a model that
SUMOylation of Aurora B is a novel mechanism to regulate its kinase activity during mitosis (Ban
et al., 2011).
Analysis of SUMOylation of the CPC in mammalian cells has revealed that its nonenzymatic subunit, Borealin, is preferentially modified by SUMO-2/3, and that the level of its
SUMOylation in metaphase is higher than that in anaphase (Table 1.1 and Figure 1.4) (Klein et
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al., 2009). Interestingly, Nup358/RanBP2 has been identified as the SUMO E3 ligase for Borealin
both in vitro and in vivo (Klein et al., 2009). Furthermore, the SUMO isopeptidase SENP3 has a
specific interaction with Borealin in vivo and is responsible for deSUMOylation of Borealin (Klein
et al., 2009). However, SUMOylation of Borealin does not affect the assembly of the CPC as well
as its localization at centromeres and spindle midzone (Klein et al., 2009). Interestingly, the yeast
Survivin homolog Bir1 has also been identified as a SUMO target, but the role of its SUMOylation
is currently unknown (Montpetit et al., 2006).


CENP-H/I/K complex at the inner kinetochore
Studies of the mammalian SUMO isopeptidase SENP6 have shown that the inner

kinetochore proteins CENP-H/I are specifically modified by polymeric SUMO-2/3 chains (Table
1.1 and Figure 1.4) (Mukhopadhyay et al., 2010). RNAi-depletion of SENP6 results in an
accumulation of the polymeric SUMO-2/3 chain-modified CENP-H and CENP-I during S phase,
rather than in mitosis (Mukhopadhyay et al., 2010; Mukhopadhyay and Dasso, 2010). Because
the CENP-H/I/K complex is recruited to the constitutive inner kinetochore structures during S
phase, it has been hypothesized that SUMOylation of CENP-H/I promotes the assembly of inner
kinetochores (Mukhopadhyay et al., 2010; Mukhopadhyay and Dasso, 2010). In SENP6-depleted
cells, the poly-SUMO-2/3 chains on CENP-H/I are recognized by RNF4, a SUMO targeted
ubiquitin ligase (STUbL), leading to polyubiquitination and proteasome-mediated degradation of
CENP-H/I (Mukhopadhyay et al., 2010). Furthermore, SENP6 depletion leads to the chromosome
congression defect, the prolonged mitotic arrest, and the chromosome missegregation in
mammalian cells (Mukhopadhyay et al., 2010). The mitotic defects in SENP6-depleted cells are
comparable to those in the CENP-H/I/K-depleted cells, suggesting that SENP6 is a key regulator
of inner kinetochore assembly by preventing the polymeric SUMO-2/3 chain modification of the
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CENP-H/I/K complex and thereby protecting CENP-H/I/K from RNF4-mediated degradation
during S phase (Mukhopadhyay et al., 2010; Mukhopadhyay and Dasso, 2010).


Nuf2, BubR1 and CENP-E at outer kinetochore and fibrous corona
Studies of mitotic SUMOylation in mammalian cells have shown that the outer kinetochore

protein Nuf2 and the fibrous corona-associated proteins BubR1 and CENP-E are specifically
modified by SUMO-2/3 (Table 1.1 and Figure 1.4) (Zhang et al., 2008). Recent studies have
shown that SUMOylation of BubR1 is essential for its function during mitosis (Table 1.1 and
Figure 1.4) (Yang et al., 2011). As a key component of the spindle assembly checkpoint (SAC),
BubR1 is localized to unattached kinetochores during early prophase and then disassociates from
microtubule-attached kinetochores following chromosome congression to the metaphase plate
(Cheeseman and Desai, 2008). BubR1 is predominantly modified by SUMO at Lysine 250
(K250), and its SUMOylation is strongly stimulated after a prolonged mitotic arrest caused by the
treatment of either nocodazole or taxol (Yang et al., 2011). Interestingly, SUMOylation of BubR1
does not regulate its kinase activity and kinetochore localization (Yang et al., 2011). However,
ectopic expression of the SUMOylation-deficient BubR1 mutant causes a defect in the timely
removal of the BubR1 mutant from the kinetochore during metaphase for SAC inactivation, which
leads to a delay of progression through mitosis, and also an increase of lagging chromosomes
during anaphase (Yang et al., 2011). These results indicate that BubR1 SUMOylation plays a
critical role in its disassociation from kinetochores, the checkpoint inactivation for timely entry of
anaphase, and therefore accurate chromosome segregation.
The highly conserved KMN network present in the outer kinetochore consists of three
complexes, Knl1, Mis12 and Ndc80 (Cheeseman et al., 2004). The components of the KMN
network are essential for viability and are important for kinetochore-microtubule attachments
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(Kline-Smith et al., 2005). The Knl1 complex comprises of KNL1 and ZWINT and Mis12 complex
consists of MIS12, NSL1, NNF1 and DSN1 (Varma and Salmon, 2012). The Ndc80/Hec1
complex, including Ndc80/Hec1, Nuf2, Spc24 and Spc25 subunits, is found at the outer
kinetochore plate and plays a major role in kinetochore-microtubule attachments (Ciferri et al.,
2007; Tooley and Stukenberg, 2011). It has been reported that Nuf2 can directly interact with
CENP-E in vitro and is also required for targeting CENP-E to kinetochores in mammalian cells
(Liu et al., 2007). Although Ndc80 has been identified as a SUMO substrate in budding yeast, the
function significance of its SUMOylation is still unknown (Montpetit et al., 2006). It would be
very interesting to know whether the mammalian Ndc80 homolog, Hec1, is also a SUMO target
in vivo. As a SUMO-2/3 substrate (Zhang et al., 2008), the BubR1 kinase is a key component of
SAC (Musacchio and Salmon, 2007) and a CENP-E interacting protein at the fibrous corona (Chan
et al., 1998; Yao et al., 2000). In addition, BubR1 and CENP-E can be co-immunoprecipitated
from HeLa cells (Chan et al., 1998; Yao et al., 2000). Interestingly, the tail domain of CENP-E is
specifically modified by SUMO-2/3, suggesting that this modification might be important for its
kinetochore localization (Zhang et al., 2008). Because the SUMOylation sites at CENP-E tail
domain have not been identified, the effect of CENP-E SUMOylation on its kinetochore
localization cannot be directly tested by using the SUMOylation-deficient CENP-E mutant (Zhang
et al., 2008).
The chromosome congression defect in SENP2 overexpressing cells is almost the same as
the defect caused by depletion or inhibition of CENP-E (Putkey et al., 2002; Wood et al., 1997;
Yao et al., 2000; Yucel et al., 2000). The chromosome congression defect is a failure in complete
chromosome alignment to the metaphase plate with some chromosomes detected at the spindle
pores. CENP-E is a plus end directed, kinesin-7 family motor protein and is found mainly
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associated with the kinetochore fibrous corona (Kapoor et al., 2006; Kim et al., 2008). CENP-E
functions in the kinetochore-microtubule attachment and plays a major role in chromosome
congression from the spindle poles to the metaphase plate (Schaar et al., 1997; Wood et al., 1997).
It has been shown that the loss of CENP-E at kinetochores in the SENP2 overexpressing cells is
caused by the defect in targeting CENP-E to kinetochores other than by the degradation of CENPE (Zhang et al., 2008). Unlike the RNAi-depletion of SENP6, SENP2 overexpression does not
affect in the overall structure and function of kinetochores, because the centromere and
kinetochore proteins (including Aurora B, Survivin, CENP-B, CENP-C, Hec1, CENP-F, Nup96
and Nup107) exhibit correctly localization on mitotic chromosomes in SENP2 overexpressing
cells (Mukhopadhyay et al., 2010; Zhang et al., 2008). In SENP2 overexpressing cells, the signals
of spindle assembly checkpoint (SAC) proteins, including Bub1, BubR1 and Mad2, are largely
undetectable on aligned chromosomes at the metaphase plate but accumulated on unaligned
chromosomes at the spindle poles, indicating that the mitotic arrest caused by SENP2
overexpression is due to the activation of SAC.


RanGAP1 at kinetochore fibrous corona
In vertebrates, SUMO-1 modification of RanGAP1 is required for the assembly of a highly

stable multiprotein complex, called the RRSU complex, which consists of RanBP2/Nup358,
RanGAP1-SUMO1 (SUMO-1-modified RanGAP1) and Ubc9 (Dasso, 2008; Mahajan et al., 1997;
Matunis et al., 1998; Reverter and Lima, 2005; Saitoh et al., 1997; Zhang et al., 2002). In
interphase cells, the unmodified RanGAP1 is localized to the cytoplasm, whereas SUMO-1
modification of RanGAP1 facilitates RanGAP1 interaction with RanBP2/Nup358 and Ubc9 at the
cytoplasmic filaments of the NPC, leading to the RRSU complex assembly (Mahajan et al., 1997;
Matunis et al., 1998; Reverter and Lima, 2005; Saitoh et al., 1997; Zhang et al., 2002). During
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mitosis, the RRSU complex is localized to kinetochore fibrous corona (Table 1.1 and Figure 1.4)
and mitotic spindles (Dasso, 2008; Joseph et al., 2002; Matunis et al., 1996). The association of
the RRSU complex with kinetochores appears immediately after nuclear envelope breakdown and
persists until the late anaphase (Joseph et al., 2002). As the key component of the RRSU complex,
RanBP2 is required for targeting RanGAP1 to the NPC during interphase and to the kinetochore
during mitosis (Joseph et al., 2004; Joseph et al., 2002; Mahajan et al., 1998; Matunis et al., 1998).

1.5 THE ASSOCIATION OF THE SUMOYLATION PATHWAY
WITH HUMAN DISEASES
Consistent with the essential roles of the SUMO pathway in many biological processes,
perturbations of SUMOylation have been implicated to human diseases including various types of
cancer and multiple neurodegenerative diseases. Any imbalance caused either in the conjugation
or deconjugation of SUMO to proteins involved in cancer metastasis can lead to tumorigenesis.
Many tumor suppressors and oncoproteins have been identified as SUMO targets. The role of
SUMO in both neurodegenerative diseases and tumorigenesis will be discussed below.

1.5.1 SUMOYLATION in neurodegenerative diseases
Neurodegenerative diseases are characterized by the loss of specific neurons in certain
parts of the brain due to the aggregation of misfolded proteins. Similar to other post-translational
modifications like phosphorylation and ubiquitination, SUMOylation is also important for
neuronal development and appropriate functioning of the central nervous system (Krumova and
Weishaupt, 2013). Although initially SUMOylation have been studied using non-neuronal cell
lines, increasing lines of evidence indicate that SUMOylation is vital for the development of the
nervous system (Dorval and Fraser, 2007) and its disruption or imbalance is associated with several
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neurodegenerative diseases including Huntington’s disease (Steffan et al., 2004), Alzheimer’s
disease (Zhang and Sarge, 2008) and Parkinson’s disease (Krumova et al., 2011).
1.5.1.1 Huntington’s disease (HD)
HD is one of the neurodegenerative diseases, where the Huttingtin (Htt) gene is mutated
having long CAG (cytosine-adenine-guanine) trinucleotide repeats. The normal gene has about
10-35 repeats of CAG, whereas the mutated version can have anywhere between 36 and 120
repeats resulting in long stretches of glutamine residues. These long mutant proteins are
fragmented into smaller segments forming aggregates resulting in loss of function of neurons. Htt
proteins can be modified by both SUMO-1 and ubiquitin on the same lysine residue. SUMO
modification of Htt stabilizes the mutant protein aggravating neurodegeneration in Drosophila,
whereas, ubiquitination of Htt leads to its degradation reducing the pathology of the disease
(Steffan et al., 2004). Inhibiting SUMOylation by targeting the identified E3 ligase would be an
ideal therapy for HD.
1.5.1.2 Alzheimer’s disease (AD)
AD is a type of neurocognitive disorder that is accompanied with a gradual death of brain
cells frequently resulting in dementia. Amyloid Precursor Protein (APP) is cleaved by β-secretase
and γ-secretase to form small peptides called Amyloid beta (Aβ). When tau proteins, most
commonly found in the neurons, become defective and fail to stabilize microtubules, it results in
AD. Misfolding and aggregation of both Aβ and tau are commonly observed in this
neurodegenerative disease. APP is modified by both SUMO-1 and SUMO-2 at Lys587 and Lys595
which are in the SUMO consensus sequence (Zhang and Sarge, 2008). The β-secretase cleavage
site is located just to the C-terminus of the SUMO modification site. It has been shown that loss
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of SUMO modification of APP increases Aβ aggregates, demonstrating that the modification
obstructs the formation of Aβ aggregates.
1.5.1.3 Parkinson’s disease (PD)
PD is a central nervous system disorder that progressively affects movement, expression
and speech. PD is associated with abnormal accumulation of α-synuclein in the brain cells in the
form of Lewy bodies. The Lys 92 and Lys 102 residues of α-synuclein were identified as the major
sites for SUMO modification. It has been demonstrated that when as little as 10% of α-synuclein
is SUMO modified, it can result in a dramatic decrease in the aggregation of the protein in vitro.
More importantly, in vivo studies indicate that the SUMO-deficient mutant of α-synuclein has
increased aggregation compared to its WT form in dopaminergic neurons (Krumova et al., 2011).
This agrees with the general idea that SUMO modification of a protein increases its solubility.

1.5.2 SUMO modification in cancer progression
1.5.2.1 Pertubations of the SUMO conjugation/deconjugation machinery in cancer
Several studies have shown that one or more components of the SUMOylation machinery
exhibit changes in expression levels, which may cause an imbalance in SUMO modification and
subsequent tumorigenesis (Figure 1.5). For example, Ubc9, the sole E2 conjugating enzyme, has
varied expression levels depending on the type of cancer. In prostate and colon cancer, Ubc9 levels
are higher; whereas in lung and breast cancer, Ubc9 levels are lower compared to their normal
respective tissues (Moschos et al., 2010). Moreover, one of the studies demonstrated that
overexpression of Ubc9 resulted in increased cancer cell growth (Mo et al., 2005). On the other
hand, the SUMO E3 ligase PIAS3 is upregulated in lung, prostate and brain tumors (Wang and
Banerjee, 2004). SUMO deconjugating enzymes SENP1 and SENP3 have also been shown to be
upregulated in prostate cancer cell lines (Cheng et al., 2006b). Furthermore, in a screen involving
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hepatocellular carcinoma, patients with lower survival rates have increased expression of the
SUMO E1 enzyme (Lee and Thorgeirsson, 2004).

Figure 5. Dysregulation of SUMOylation in tumorigenesis. Altered expression in any of the components of the
SUMO pathway can lead to dysregulation of SUMOylation. This imbalance in SUMO-modified substrates (oncogenes
or tumor suppressors) can lead to cancer progression and tumorigenesis.

1.5.2.2 SUMOylation in cancer metastasis
Cancer metastasis is the process in which primary tumor cells spread to distant sites and
establish secondary tumors. It is not unexpected that SUMO modification has been implicated in
cancer metastasis. KAI1 is a metastatic suppressor gene whose transcriptional expression is
activated and repressed by the co-activator Tip60 and the β-catenin/reptin complex, respectively
(Kim et al., 2005). Reptin is SUMO modified at Lys456, and the SUMO isopeptidase SENP1 is
responsible for its deSUMOylation (Kim et al., 2006). SUMO modification of reptin alters the
metastatic potential of KAI1 in prostate cancer cells. Wild-type reptin has better interaction with
HDAC1 compared to its SUMO-deficient variant. SUMO-modified reptin represses KAI1
expression by recruiting HDAC1, resulting in enhanced invasion of LNCaP cells. This study
establishes a direct link between SUMOylation and cancer metastasis (Kim et al., 2006).
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Moreover, SUMO-modified reptin levels are higher in metastatic prostate cells LNCaP compared
to normal epithelial prostate cells RWPE1. This is probably because of lower levels of SENP1 and
higher levels of Ubc9 in LNCaP cells compared to RWPE1 cells.
1.5.2.3 SUMOylation in tumorigenesis
Several proteins involved in cancer progression, including pRb, p53, PML, BRCA1,
RhoGDI, Rac1, and Merlin, are known SUMO targets whose SUMOylation regulates cancer
metastasis in different types of cancer (Kim and Baek, 2006; Seeler et al., 2007). Retinoblastoma
protein (pRb) is a tumor suppressor that binds and thus inhibits the E2F family of transcription
factors. As long as pRb is bound to E2F factors, the cell cannot enter S- phase and is stalled in G1
phase. Also pRb-E2F dimer can recruit HDACs thereby bringing about further repression. SUMO
deficient mutant of pRb represses the E2F dependent reporter genes more efficiently than its WT
counterpart. (Ledl et al., 2005). The authors therefore hypothesize that SUMO modification on
pRb displaces E2F family transcription factors. It would be interesting to investigate if SUMO
modification of pRb is higher in cancer cells compared to normal epithelial cells.
BRCA1 (Breast Cancer 1 predisposition protein) is mutated in different types of breast
cancer. BRCA1 is recruited at DNA double strand breaks and repairs damaged DNA. Moreover,
it is a ubiquitin E3 ligase whose activity is required for tumor suppression (Morris et al., 2006).
SUMO modification of BRCA1 increases its E3 ligase activity (Morris et al., 2009). Hence,
BRCA1 is considered as a SUMO-regulated ubiquitin E3 ligase (Morris et al., 2009).
Merlin (Moesin-Ezrin-Radixin like protein) is a cytoskeleton protein and has tumor
suppressor activity in humans. It is predominantly located in the nervous tissue, whose mutations
result in the development of tumors in the nervous system and neurofibromatosis (Ruttledge and
Rouleau, 2005). It regulates various signaling pathways controlling cell proliferation and
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migration. Merlin is generally found in the plasma membrane, whereas SUMO deficient mutant
of Merlin was found in the cytosol. SUMOylation of Merlin is required for its stability and in a
xenograft mouse model, merlin sumoylation was found to be important for tumor suppressing
activity (Qi et al., 2014).
Rac1 belongs to the Rho family of GTPases and has been shown to play a role in cell
motility and adhesion by making the cytoskeletal rearrangements and the formation of
lamaellipodia. Mutations of Rac1 are found in several cancers including breast cancer and nonsmall cell lung cancer which leads to enhanced cell migration leading to cancer metastasis
(Schnelzer et al., 2000). This is one of the examples of SUMO-1 modification taking place in a
non-consensus motif of Rac1. Overexpression of PIAS3 upregulates SUMO modification of Rac1
in response to hepatocyte growth factor (HGF) and this leads to increased lamellipodia formation
and cell migration compared to controls (Castillo-Lluva et al., 2010). This clearly indicates the
role of SUMOylation in cell migration and cancer metastasis.
The Rho-GDP dissociation inhibitor RhoGDI binds to the GDP bound form of RhoGTPase
(inactive form). The RhoGTPases, including RhoA, Rac1 and Cdc42, play an important role in
cell migration, invasion, lamellipodia formation through actin cytoskeleton reorganizations, and
their functions are inhibited by RhoGDI binding. Recently, RhoGDI was identified as a SUMO
target. The cells transfected with RhoGDI WT had decreased rates of cell invasion compared to
cells transfected with RhoGDI K138R, the SUMOylation-deficient mutant. Therefore, SUMO
modification of RhoGDI increases its inhibitory effects on cell migration (Yu et al., 2012).
1.5.2.4 Cancer therapy through the SUMO pathway
Myc is a proto-oncogene, whose product is a transcription factor. Myc is known to be
mutated and over-expressed in several cancers (Gurel et al., 2008; Palaskas et al., 2011), leading
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to upregulation of its downstream genes some of which are involved in cell proliferation. On the
other hand, KRAS is a small GTPase playing a role in signal transduction pathways and its mutated
version is often found in cancers (Bos et al., 1987). Direct targeting and inhibition of these two
oncoproteins have been shown to be highly difficult, suggesting that it is necessary for developing
alternative approaches.
A genome-wide RNAi screen was performed to identify the genes that show synthetic
lethality with Myc hyperactivation (Kessler et al., 2012). It was found that loss of the SUMO E1activating enzyme subunit SAE2 is synthetic lethal with overexpression of Myc. Furthermore, the
authors found that RNAi-depletion of SAE2 in cells with Myc overexpression causes mitotic
aberrations with spindle defects. In addition, the metastasis-free survival rate of human breast
cancer patients with high-Myc expression and low-SAE2 levels are much higher than those with
high-Myc expression and high-SAE2 levels (Kessler et al., 2012). Together these data suggest that
targeting SAE2 can be an approach to treat cancer with hyperactivated Myc.
Another genome-wide screen in KRAS mutant cells identified both SAE1 and Ubc9 as its
synthetic lethal partners (Luo et al., 2009). A following study demonstrated that Ubc9 is important
for both anchorage dependent and anchorage independent clonogenic growth of KRAS mutant
colorectal tumor cells and it aids KRAS-mediated transformation (Yu et al., 2015). These data
suggest that the components of the SUMO pathway could be potential therapeutic targets for
treating cancers in which KRAS is mutated.

1.6 PROJECT OUTLINE
At the end of a cell cycle in a somatic eukaryotic cell, each cell divides into two. A loss of
control of cell-cycle progression often leads to uncontrolled cell proliferation and cancer
development. Several lines of evidence suggest that SUMOylation of various proteins involved in
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cell cycle regulation are critical for accurate cell cycle progression through mitosis. As mentioned
above there are also a number of tumor suppressor and oncogenes that are bona fide SUMO targets.
In order to understand the role of SUMOylation in cancer progression, I developed a
technique called SUMO-epitope-peptide elution (SUMO-ePIPE), which in combination with mass
spectrometry was employed for the purification and identification of SUMO-2/3 targets in two
different mouse breast cancer cell lines, which is described in Chapter 2. About 66 SUMOmodified protein targets have been identified, and they are involved in different biological
processes including cell migration, stress response, gene expression, cell cycle and metabolism.
Out of the 66 targets, about 10 of them were confirmed as bona fide SUMO-2/3 substrates using
either in vitro or in vivo approaches. Furthermore, we showed that global SUMO-2/3 upregulation
stimulates 3D cell migration.
Uncontrolled cell division is a hallmark of human cancers. In Chapter 3, I therefore
concentrated on the importance of SUMOylation in cell division by primarily focusing on the
regulation of cell-cycle progression through mitosis. We found that polymeric SUMO-2
modification but not polymeric SUMO-1 modification at the centromere/kinetochore region is
required for CENP-E targeting to kinetochores and chromosome alignment to the metaphase plates
in cells with inhibition of SUMOylation by overexpressing the isopeptidase SENP2 or by depleting
the sole E2 enzyme Ubc9. Also, using biochemical assays, we found that a kinetochore protein
Nuf2 which has three SUMO-2 moieties fused to its C-terminus has a higher binding-affinity to
CENP-E compared to Nuf2 alone, suggesting that polymeric SUMO-2 chain modification of Nuf2
recruits CENP-E to kinetochores by enhancing the interaction of Nuf2 with CENP-E.
We found that a minimum of trimeric SUMO-2 chain fused to Nuf2 is essential for
chromosome alignment and CENP-E recruitment to kinetochores in cells overexpressing SENP2.
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However, it is not known if a longer length of polymeric SUMO-2 chain (4xSUMO-2 and
5xSUMO-2) fused with Nuf2 can achieve a greater rescue in cells with overexpression of SENP2.
This can be tested by co-transfecting cells with SENP2 along with either Nuf2-4xSUMO-2 or
Nuf2-5xSUMO-2. Another area to explore would be to test if other putative SIMs on CENP-E
have SUMO-2 binding activity and if they are required for CENP-E localization to the
kinetochores. In an effort to identify the E3 ligase for the regulation of Nuf2 SUMOylation, an in
vitro binding assay between Nuf2 and the different PIAS proteins indicated that both PIASxα and
PIASy interacted with Nuf2. It would be interesting to test if PIASxα or PIASy regulate the
SUMO-2 modification of Nuf2. These future directions are discussed in Chapter 4.
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CHAPTER 2 ANALYSIS OF CHANGES IN SUMO-2/3
MODIFICATION DURING BREAST CANCER PROGRESSION
AND METASTASIS
This chapter has been published in Journal of Proteome Research.

2.1 ABSTRACT
SUMOylation is an essential posttranslational modification and regulates many cellular
processes.

Dysregulation of SUMOylation plays a critical role in metastasis, yet how its

perturbation affects this lethal process of cancer is not well understood. We found that SUMO2/3 modification is greatly up-regulated in metastatic breast cancer cells compared to nonmetastatic control cells. To identify proteins differentially modified by SUMO-2/3 between
metastatic and non-metastatic cells, we established a method in which endogenous SUMO-2/3conjugates are labeled by stable isotope labeling by amino acids in cell culture (SILAC),
immunopurified by SUMO-2/3 monoclonal antibodies and epitope-peptide elution, and analyzed
by quantitative mass spctrometry. We identified 66 putative SUMO-2/3-conjugated proteins, of
which 15 proteins show a significant increase/decrease of SUMO-2/3 modification in metastatic
cells. Targets with altered SUMOylation are involved in cell cycle, migration, inflammation,
glycolysis, gene expression and SUMO/ubiquitin pathways, suggesting that perturbations of
SUMO-2/3 modification might contribute to metastasis by affecting these processes. Consistent
with this, up-regulation of PML SUMO-2/3 modification corresponds to an increased number of
PML nuclear bodies (PML-NBs) in metastatic cells, whereas up-regulation of global SUMO-2/3
modification promotes three-dimensional (3D) cell migration. Our findings provide a foundation
for further investigating the effects of SUMOylation on breast cancer progression and metastasis.
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2.2 INTRODUCTION
SUMOylation is an essential posttranslational modification characterized by covalent
conjugation of SUMO proteins to many different proteins in eukaryotes. By tightly regulated
cycles of conjugation and deconjugation, SUMOs act as molecular switches for controlling protein
activity, localization, stability, and/or protein-protein interaction (Gareau and Lima, 2010; GeissFriedlander and Melchior, 2007; Hay, 2005; Wang and Dasso, 2009; Yeh, 2009). SUMOylation
has emerged as a major regulatory mechanism for a variety of cellular processes including cell
cycle control, cell migration, gene expression, DNA repair, signal trasnduction and stress response
(Gareau and Lima, 2010; Geiss-Friedlander and Melchior, 2007; Hay, 2005; Wang and Dasso,
2009; Yeh, 2009). SUMO is conjugated to a substrate using E1-activating enzyme (SAE1/SAE2),
an E2-conjugating enzyme (Ubc9), and multiple E3 ligases (Gareau and Lima, 2010; GeissFriedlander and Melchior, 2007; Hay, 2005; Wang and Dasso, 2009; Yeh, 2009). Furthermore,
SUMOs are deconjugated from their substrates by SUMO-specific isopeptidases (Gareau and
Lima, 2010; Geiss-Friedlander and Melchior, 2007; Hay, 2005; Wang and Dasso, 2009; Yeh,
2009). Proteomic analyses have revealed that SUMO-1 and SUMO-2/3 are conjugated to distinct
and overlapping sets of proteins, indicating that SUMO-1 and SUMO-2/3 modifications may
regulate both unique and redundant biological processes (Vertegaal et al., 2006). During mitosis,
SUMO-2/3-modified proteins are uniquely localized on mitotic chromosomes including
centromeres and kinetochores, whereas SUMO-1-modified proteins are associated with the mitotic
spindle and spindle midzone, indicating that SUMO-1 and SUMO-2/3 are conjugated to different
target proteins and thereby play distinct mitotic functions (Wan et al., 2012a; Zhang et al., 2008).
Both SUMO-2/3, but not SUMO-1, contain a SUMOylation consensus motif (ΨKxE/D)(Ψ is a
large hydrophobic amino acid, K is the lysine residue that is modified, x is any residue, and E or
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D is an acidic residue), which is responsible for the formation of polymeric SUMO-2/3 chains
(Ulrich, 2008; Vertegaal). However, the molecular mechanisms underlying these paralog-specific
modifications are still not well understood.
Accumulating lines of evidence support the idea that balanced levels of SUMO-modified
and unmodified proteins are required for normal cellular processes, whereas an imbalance in
SUMOylation often results in human diseases including cancer (Bawa-Khalfe et al., 2010; BawaKhalfe et al., 2012; Bawa-Khalfe and Yeh, 2010; Driscoll et al., 2009; Kessler et al., 2012; Kim et
al., 2006; Kim and Baek, 2006; Mo et al., 2005; Wang and Banerjee, 2004; Yang et al., 2013).
Consistent with this model, dysregulation of SUMOylation caused by overexpression of SUMOconjugating and/or deconjugating enzymes is frequently associated with advanced stages of cancer
and low survival rates (Bawa-Khalfe and Yeh, 2010; Kessler et al., 2012). Furthermore, many
proteins, including promyelocytic leukemia (PML), BRCA1, estrogen receptor, p53, Rac1 and
RhoGDI, which play a critical role in tumorigenesis and metastasis, have been identified as
SUMO-modified substrates.(Boddy et al., 1996; Castillo-Lluva et al., 2010; Gostissa et al., 1999;
Kamitani et al., 1998; Morris et al., 2009; Muller et al., 1998; Rodriguez et al., 1999; Sentis et al.,
2005; Sternsdorf et al., 1997; Yu et al., 2012) Moreover, human genome-wide RNAi screens of
Myc or Ras synthetic lethal genes have revealed that SUMOylation is required for tumorigenesis
driven by Myc hyperactivation or Ras mutations (Kessler et al., 2012; Luo et al., 2009). Because
Ras and Myc oncoproteins are difficult to inhibit pharmacologically, targeting the SUMO pathway
may have therapeutic efficacy for cancers driven by Myc and/or Ras oncogenes (Kessler et al.,
2012; Luo et al., 2009). Recent studies revealed that dysregulation of SUMOylation promotes
cancer cell proliferation, migration, invasion and metastasis, (Bawa-Khalfe et al., 2012; Kessler et
al., 2012; Kim and Baek, 2006; Luo et al., 2009) yet how an imbalance in SUMOylation
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contributes to the important processes of cancer is not well understood.
Using a well-established mouse breast cancer progression and metastasis model,(Aslakson
and Miller, 1992) we found that SUMO-2/3 modification is greatly up-regulated in metastatic cells
compared to non-metastatic control cells. To specifically purify endogenous SUMO-conjugates
in these breast cancer cells, we first developed an affinity-purification technique called “SUMOepitope-peptide elution” (SUMO-ePIPE). Recently, Melchior and colleagues (Becker et al., 2013)
have described a technique that is similar to our SUMO-ePIPE approach. However, a proteomic
method has not been established or applied for the identification of proteins that are differentially
modified by endogenous SUMOs between two biological samples, such as metastatic and nonmetastastic cells. To identify the target proteins differentially modified by SUMOs between
metastatic and non-metastatic cells, we developed a proteomic strategy by coupling SUMO-ePIPE
with SILAC (stable isotope labeling by amino acids in cell culture) and quantitative mass
spectrometry analysis (Olsen and Mann, 2013). Using this strategy, we resolved a network of
proteins that are differentially modified by SUMO-2/3 in metastatic breast cancer cells when
compared to non-metastatic control cells. The identified proteins are involved in multiple cellular
processes including cell cycle, cell migration, gene expression, glycolysis, inflammation, stress
response, and SUMO/ubiquitin pathways. Furthermore, we verified a list of SUMO targets by in
vitro SUMOylation assays and also confirmed that the SUMO-2/3 modification of PML,
Macrophage Migration Inhibitory Factor (MIF), α-Enolase, Pyruvate kinase M2 (PKM2) and
hnRNPU is significantly enhanced in metastatic cells compared to non-metastatic cells. Moreover,
we found that up-regulation of PML SUMO-2/3 modification is associated with an increased
assembly of PML-NBs in metastatic cells when compared to non-metastatic cells. Lastly, in
support of our proteomic results suggesting a link between SUMO-2/3 modification and cell
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migration, we demonstrated that up-regulation of global SUMO-2/3 modification by
overexpressing GFP-SUMO-2/3 in breast cancer cells significantly increased the linear speed of
3D migration.

2.3 MATERIALS AND METHODS
Primers, Plasmids, Antibodies and Peptides
PCR primers were used to amplify different fragments of human SUMO-1 and SUMO-2
and also to generate non-conjugatable SUMO-2 and SUMO-3 mutants by site-directed
mutagenesis (Appendix A Table A.1, A.2 and A.3). Gateway entry plasmids were purchased from
DNA Plasmid Repository at Arizona State University (DNASU), control and epitope peptides for
SUMO-ePIPE were chemically synthesized (Bio-Synthesis), and antibodies for Western blotting
(WB) and immunofluorescence microscopy (IF) were listed (Appendix A Table A.4, A.5, A.6).

Cell Culture and SILAC Method
All the mouse breast cancer cell lines including 67NR, 168FARN, 4TO7 and 66cl4 (a gift
from Dr. Fred Miller, Karmanos Cancer Institute, Wayne State University) were grown in DMEM
(HyClone) media supplemented with 10% FBS (Invitrogen) and 1% Pencillin-Streptomycin
(Invitrogen) and maintained at 37oC. For immunopurification of SUMO-2/3 conjugates using
SUMO-2/3-ePIPE, 168FARN and 66cl4 cells were SILAC labeled in light (Arg0 and Lys 0) and
heavy (Arg10 and Lys8) media (Cambridge Isotope Laboratories), respectively (Tatham et al.,
2011). The final concentration of all the isotopes was 0.26 mM. The cells were grown for eight
passages on the SILAC media before SUMO-2/3-ePIPE. In addition, mass spectrometry was used
to confirm that the proteins in 66cl4 cells were incorporated with the heavy isotopes.
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Purification of Endogenous SUMO-Conjugates by SUMO-ePIPE
Cells were lysed under a stringent denaturing condition and used for immunopurification
of endogenous SUMO-1 and SUMO-2/3 conjugates using anti-SUMO-1 (21C7) (Matunis et al.,
1996) and anti-SUMO-2/3 (8A2) (Zhang et al., 2008) mAbs (Appendix A Table A.6) that were
crosslinked to Protein-G beads using Disuccinimidyl suberate (DSS) (Thermo Fisher Scientific).
SUMO-1-ePIPE and SUMO-2/3-ePIPE were used to elute endogenous SUMO-1 and SUMO-2/3
conjugates from the beads using SUMO-1 and SUMO-2/3 epitope peptides, respectively
(Appendix A Table A.5).

For quantitative proteomic analyses of endogenous SUMO-2/3

conjugates, 50 plates (150 mm) of SILAC-labeled 168FARN (Light) or 66cl4 cells (Heavy) were
respectively lysed in 1× Lysis Buffer along with protease inhibitors and 20 mM NEM as described
(Zhang et al., 2008). The 1× Lysis Buffer was obtained by diluting 2× SSB (5% SDS, 150 mM
Tris-HCl pH 6.7, 20% glycerol) with 1× RIPA buffer (20 mM HEPES pH 8.0, 300 mM NaCl, 2
mM EDTA, 0.5% Sodium deoxycholate, 1% Triton X-100, and 6% glycerol) in 1:4 ratio. For
every four plates, 3 ml of 1× Lysis Buffer was used. The whole cell lysates were sonicated and
ultra-centrifuged at 100,000× g for 1 h at 4oC. After centrifugation, the supernatant was passed
through a 0.22 μm filter. The filtered lysates from the two cell lines were mixed in an equal ratio
(1:1) of total proteins, diluted with 1× RIPA buffer to reduce the SDS concentration to 0.1%, and
loaded onto a column containing 2 ml of Protein G beads crosslinked with 8A2 mAbs. After
binding, the beads were washed with 100 ml of wash buffer (20 mM HEPES pH 8.0, 750 mM
NaCl, 2 mM EDTA, 0.5% Sodium deoxycholate, 1% Triton X-100, 6% glycerol, 0.1% SDS, and
10 mM NEM). Elution was performed with either the control or SUMO-2/3-epitope peptides ((0.2
mg/ml) (Bio-Synthesis) (Appendix A Table A.5) in 1× Elution Buffer (20 mM HEPES pH 8.0,
100 mM NaCl, 5% glycerol, and 2 mM EDTA). The eluted proteins were precipitated by
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trichloroacetic acid (TCA) and dissolved in 2× SSB for immunoblotting, silver staining,
Coomassie blue staining and quantitative mass spectrometry.

Proteomic Analysis
The following was performed by our collaborators (Dr. Jesper Oslen’s laboraotry) at
University of Copenhagen, Denmark. To identify the proteins that are differentially modified by
endogenous SUMO-2/3 between SILAC-labeled metastatic and non-metastatic cells, the gel slices
in Figure 2.8D were in-gel digested with trypsin as described (Lundby and Olsen, 2011). Briefly,
the excised gel slices were minced and destained (50% 25 mM ammonium bicarbonate, 50%
acetonitrile for 3 times 20 min, 800 rpm, room temperature (RT)) and dehydrated (acetonitrile, 10
min, 800 rpm) followed by reduction of disulfide bonds (10 mM dithiothreitol in 25 mM
ammonium bicarbonate, 45 min, RT, 800 rpm) and alkylation of cysteines (55 mM chloroacetamide in 25 mM ammonium bicarbonate, 30 min, 24 °C in darkness, 800 rpm). After washing
in 25 mM ammonium bicarbonate the gel plugs were dehydrated in acetonitrile and proteins were
digested with trypsin (50 μL 12.5 ng/μL sequencing grade trypsin from Promega in 25 mM
ammonium bicarbonate overnight at 37 °C). Trypsin activity was quenched by acidification with
a 10% trifluoroacetic acid (TFA) solution to pH~2 and peptides were extracted from the gel plugs
with 30% acetonitrile in 3% trifluoroacetic acid (30 min, 800 rpm) followed by 80% acetonitrile
in 0.5% acetic acid (30 min, 800 rpm) and finally in 100% acetonitrile. Organic solvents were
removed by evaporation in a vacuum centrifuge. Extracted peptides were desalted and
concentrated on STAGE-tips with reversed-phase C18 filters. The Peptide fractions were analyzed
by online nanoflow liquid chromatography tandem mass spectrometry (nanoLC-MS/MS) on an
LTQ Orbitrap Velos instrument essentially as described (Olsen et al., 2009). Peptides were eluted
from the STAGE tips into 96 well microtiterplates with 2×20 μL 40% acetonitrile in 0.5% acetic
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acid and the acetonitrile was evaporated using a vacuum centrifuge reducing the sample volume
to 4 μL. Online peptide separation was performed by reversed-phase C18 HPLC on an Easy nLC
system (Thermo Fisher Scientific) in a 15 cm long analytical column packed with 3 µm C18 beads,
and eluting peptides using a 45 min segmented gradient of increasing (5%-80%) buffer B (80%
acetonitrile in 0.5% acetic acid) at a constant flow of 250 nl/min. The effluent from the HPLC was
directly electrosprayed into an LTQ Orbitrap Velos mass spectrometer (Thermo Fisher Scientific)
through a nano-spray ion source. The peptide mixture was analyzed by full-scan MS spectra (m/z
300-2000, resolution 30,000) in the Orbitrap analyzer after accumulation of 1,000,000 ions in the
Orbitrap within a maximum fill-time of 1.000 ms. For every full-scan the ten most intense peptide
ions were sequentially isolated and fragmented by higher energy collisional dissociation (HCD)
and fragments were recorded by the orbitrap mass analyzer after accumulation of 50,000 ions with
a maximum fill-time of 250 ms and using a normalized collision energy of 40%. The acquired
MS raw data was processed by MaxQuant version 1.2.7.5 (www.maxquant.org), where peptides
and proteins are identified by the Andromeda search algorithm via matching of all MS and MS/MS
spectra against a target/decoy-version of the Uniprot human and mouse databases supplemented
with reversed copies of all sequences as well as frequently observed contaminants. Maximal
MS/MS tolerance was 20 ppm, a maximum of 2 missed cleavages was allowed.
Carbamidomethylated cysteines were set as a fixed modification, whereas N-pyroglutamine,
oxidation of methionine and N-terminal acetylation were searched as variable modifications.
Minimum peptide length was set at 7 amino acids. Peptide quantitation, statistical evaluation and
filtering of the resulting peptide datasets were performed in MaxQuant to achieve a FDR<0.01.
Protein ratios were calculated as the mean of the SILAC ratios determined for all individual
peptides for each protein.
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Gene Ontology and Functional Networks
The STRING (Search Tool for Retrieval of Interacting Genes/Proteins) database (Version
9.1) (Franceschini et al., 2013) was used for analyzing gene ontology and functional networks of
the putative SUMO substrates identified by SUMO-2/3-ePIPE and mass spectrometry. The known
direct and indirect protein-protein interactions within these substrates were identified with a high
confidence level of 0.7.

In vitro SUMOylation Assays
The DNA inserts encoding SUMO substrates were transferred from the entry plasmids
(DNASU) (Appendix A Table A.4) to the destination vector pDEST15 using Gateway cloning
technology according to the manufacturer’s instructions (Invitrogen). The generated destination
plasmids were transformed into E. coli BL21 (DE3) cells alone or co-transformed with the pTE1E2S2 plasmid encoding SUMO E1, E2 and SUMO-2 as described (Uchimura et al., 2004).
After induction with IPTG at a final concentration of 0.1 mM for 4 h, the GST tagged proteins
were pulled down using Glutathione Sepharose beads (GE Healthcare). The eluted proteins were
analyzed by immunoblotting with anti-GST and anti-SUMO-2/3 antibodies. In addition, in vitro
SUMO-1 and SUMO-2 modifications of GST-tagged Vimentin and FLAG-tagged Myosin-12
motor domain were analyzed by incubating with recombinant SUMO-E1 and Ubc9 in the presence
or absence of SUMO-1/SUMO-2 for 2 h at 37 oC and by immunoblotting with anti-GST and antiFLAG antibodies as described (Zhang et al., 2008).

3D Cell Migration Assays
Three dimensional (3D) collagen migration assays were performed as previously described
(Indra et al., 2011). 168FARN cells were either transfected with GFP empty vector or cotransfected with GFP-SUMO-2 and GFP-SUMO-3 wild-type (WT) or non-conjugatable mutant
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using Lipofectamine-Plus reagent according to the manufacturer’s instructions (Invitrogen). After
24-36 hours of transfection, cells were suspended in buffered liquid collagen type I (1.5 mg/ml,
pH 7.4) (Advanced Biomatrix) and seeded on glass chambers for polymerization at 37 °C. The
168FARN cells expressing GFP or GFP-SUMO-2/3 were identified by fluorescence microscopy
using the Olympus IX81 ZDC inverted microscope. The migration of a single transfected cell was
monitored at 37 °C by time-lapse phase-contrast video microscopy with a 40×/0.75 NA PlanNeofluar lens. The phase-contrast images of each cell were captured at 2 min intervals over a 120
min period. 10 sets of time-lapse microscopy videos of 168FARN cells expressing either GFP or
GFP-SUMO-2/3 WT or mutant were used to calculate the linear speed of cell migration (μm/min)
with each bar representing the mean value ± SEM.

Immunofluorescence Microscopy
To accurately compare the morphologies of the four mouse breast cancer cells, the
adhesion of these cells on coverslips was enhanced by incubating the coverslips in PBS containing
50 μg/ml collagen (BD Biosciences), 50 μg/ml fibronectin (Sigma) and 10 μg/ml BSA (bovine
serum albumin) (Sigma) at RT for 2 h. These coated coverslips were then used for growing cells.
Once the cells were fixed with 3.5% paraformaldehyde for 10 min, they were permeabilized with
0.2% Triton X-100 for 10 min, incubated with mouse anti-SUMO-1 (21C7) or SUMO-2/3 (8A2)
primary antibodies at RT for 1 h in PBS containing 2% BSA, washed three times in PBS, and then
incubated with Alexa Fluor 488-conjugated goat anti-mouse IgG secondary antibodies
(Invitrogen) at RT for 30 min in PBS containing 2% BSA. To compare the assembly of PML
nuclear bodies (PML-NBs) between 168FARN and 66cl4 cells, cells were fixed at RT for 20
minutes in PBS containing 2% formaldehyde, and then permeabilized at RT for 10 min in PBS
containing 0.5% Triton X-100. Cells were incubated with rabbit anti-PML antibodies (Santa Cruz)
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and mouse anti-SUMO-2/3 mAbs (8A2). Olympus inverted IX81 fluorescence microscope was
used to take images. To specifically analyze the cytoplasmic distribution of SUMO-1 and SUMO2/3 in breast cancer cells, non-metastatic 168FARN and metastatic 66cl4 cells were fixed with
3.5% paraformaldehyde at RT for 30 min, incubated with 0.04% digitonin at RT for 10 min to
selectively permeabilize cell membrane but not nuclear envelope, double labeled with rabbit antiRanGAP1 antibodies and mouse anti-SUMO-1 (21C7) or anti-SUMO-2/3 (8A2) mAb, and
analyzed by indirect immunofluorescence microscopy.

2.4 RESULTS
2.4.1 Dysregulation of SUMOylation during Breast Cancer Progression and
Metastasis
To test if SUMOylation is differentially regulated during breast cancer development, I
performed immunoblot analysis to compare both SUMO-1 and SUMO-2/3 modifications among
three non-metastatic (67NR, 168FARN, and 4TO7) and one metastatic (66cl4) isogenic mouse
breast cancer cell line (Aslakson and Miller, 1992). These cells are derived from a single
mammary tumor that spontaneously formed in a wild-type BALB/c mouse, and exhibit
sequentially increasing metastatic capacity after injection of these cells into the mouse mammary
fatpads (Aslakson and Miller, 1992). The different behaviors of these cell lines reflect the distinct
steps of the metastatic process from the primary mammary tumor to the secondary lung metastases
(Figure 2.2A) (Aslakson and Miller, 1992). The metastatic process of carcinoma, such as breast
cancers, has been proposed to be classified into the following distinct steps: (1) Invasion - Primary
tumor cells lose cell-cell adhesion, gain motility and invade surrounding tissue; (2) Intravasation
- Tumor cells enter the systemic circulation by penetrating through the blood and/or lymphatic
vessels, (3) Extravasation - Some of these tumor cells that survive during the circulation
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extravasate through the capillary vessels at distant sites/organs; and (4) Metastatic growth - A
small subset of these metastasizing cells are able to survive, proliferate and establish secondary
tumors (Aslakson and Miller, 1992; Yang et al., 2004). Among the three non-metastatic cells,
which are defined by their failure to establish secondary tumors, 67NR cells are primary tumor
cells incapable of local invasion, whereas both 168FARN and 4TO7 cells are capable for local
invasion and also intravasation but only 4TO7 cells can extravasate the circulatory system. In
contrast, 66cl4 cells can establish secondary tumors in lung and are thus metastatic. Interestingly,
we found that levels of SUMO-2/3 modification in metastatic 66cl4 cells were significantly upregulated compared to the three non-metastatic cells (Figure 2.1). In addition, levels of free
SUMO-2/3 were also notably elevated in metastatic cells. On the other hand, levels of SUMO-1
modification were down-regulated in 66cl4 cells relative to 168FARN, 4TO7 and 67NR cells.
Consistent with previous findings, (Indra et al., 2011) N-Cadherin was specifically expressed in
67NR and 66cl4 cells (Figure 2.2B).

Figure 2.1. Dysregulation of SUMOylation during breast cancer progression and metastasis. Total cell lysates
of four indicated breast cancer cell lines derived from the same primary tumor and with increasing metastatic capacity
were analyzed by immunoblotting with antibodies specific to SUMO-1, SUMO-2/3, Ubc9 and α-Tubulin. Notes: -,
non-metastatic cells; +, metastatic cells.

Furthermore, we found that cells from each cell line showed unique morphologies under
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phase-contrast microscopy (Figure 2.2C and D). We first fixed the cells with paraformaldehyde
and then permeabilized both cell membrane and nuclear envelope with 0.2% Triton X-100 before
indirect immunofluorescence analysis. Although both SUMO-1 and SUMO-2/3 were mainly
localized in the nucleus for each cell line, their cytoplasmic staining was obvious as well. The
relatively weak cytoplasmic staining of SUMO-1 and SUMO-2/3 might be overshadowed or
interfered by their dominant nuclear staining. In order to better detect and also to compare the
cytoplasmic SUMO-1 and SUMO-2/3 staining between non-metastatic 168FARN and metastatic
66cl4 cells, both cells were first fixed with paraformaldehyde but then incubated with a low
concentration of digitonin, a detergent that preferentially permeabilizes cell membrane but not
nuclear envelope (Matunis et al., 1996). Using this approach, we were able to detect the relatively
strong cytoplasmic staining of SUMO-1 and SUMO-2/3 in both cells that were double labeled by
rabbit anti-RanGAP1 and mouse anti-SUMO-1 or anti-SUMO-2/3 mAbs and analyzed by indirect
immunofluorescence microscopy (Figure 2.2E and F). Because it has been shown previously that
RanGAP1 is localized at the cytoplasmic filaments of nuclear pore complexes (Mahajan et al.,
1997; Matunis et al., 1996) and also at the cytoplasmic pore complexes of annulate lamellae, their
immunofluorescence staining at the nuclear envelope and the annulate lamellae can be used as a
marker for the permeabilization of cell membrane (Figure 2.2E and F). We found that the
cytoplasmic staining of SUMO-1 and SUMO-2/3 is overall slightly stronger in 66cl4 cells than in
168FARN cells.
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Figure 2.2. The subcellular distributions of SUMO-conjugates among four mouse breast cancer cell lines
derived from the same primary tumor. (A) The four mouse breast cancer cell lines, including 67NR, 168FARN,
4TO7 and 66cl4, are listed here with increasing metastatic capacities. While 67NR, 168FARN and 4TO7 are nonmetastatic, 66cl4 cells are metastatic with the capacity to form secondary tumors in lung. (B) Whole cell lysates of
the four breast cancer cells were used for immunoblot analysis with antibodies specific to N-Cadherin and α-Tubulin.
(C and D) The four breast cancer cells were fixed with formaldehyde, permeabilized with Triton X-100, stained with
mAbs specific to SUMO-1 (21C7) (C) or SUMO-2/3 (8A2) (D), and analyzed by immunofluorescence microscopy.
Distinct morphologies were observed among these cells using phase-contrast microscopy. Nuclear DNA was stained
with DAPI (4´,6-diamidino-2-phenylindole). (E and F) Non-metastatic 168FARN and metastatic 66cl4 cells were
fixed with paraformaldehyde, incubated with a low concentration of digitonin to preferentially permeabilize cell
membrane but not nuclear envelope, double labeled with rabbit anti-RanGAP1 antibodies and mouse anti-SUMO-1
(21C7) (E) or anti-SUMO-2/3 (8A2) mAb (F), and analyzed by indirect immunofluorescence microscopy. Bar, 10
μm.
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2.4.2 Broad Application of SUMO-Epitope-Peptide Elution for Purification of
Endogenous SUMO-Conjugates from Human to Drosophila and from
Cultured Cells to Tumor Samples
To identify proteins differentially modified by endogenous SUMOs between metastatic
and non-metastatic cells, we established an affinity purification technique that we refer to as
“SUMO-epitope-peptide elution” (SUMO-ePIPE) (Figure 2.3A). This technique, similar to the
one recently developed by Melchior and colleagues (Becker et al., 2013), utilizes two widely used
and commercially available mAbs specific to SUMO-1 (21C7) (Matunis et al., 1996) (Invitrogen)
and SUMO-2/3 (8A2) (Zhang et al., 2008) (Abcam). Consistent with their findings (Becker et al.,
2013), we found that the SUMO-1 epitope recognized by mAb 21C7 lies between amino acids 5567 , and the SUMO-2 epitope for mAb 8A2 locates between amino acids 58-69 (Figure 2.4 and
2.5). We also established that the SUMO-1 and SUMO-2 epitope peptides could be used to
effectively and specifically elute endogenous SUMO-1 and SUMO-2/3 conjugates that were
immunoprecipitated from human 293T cell lysates using 21C7 and 8A2 mAbs cross-linked to
Protein-G beads, respectively (Figure 2.3B).

Figure 2.3. A method for purification and identification of the proteins that are differentially modified by
endogenous SUMO-2/3 between metastatic and non-metastatic breast cancer cells. (A) A model elucidates how
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SUMO-ePIPE can be used for purification of endogenous SUMO-conjugates. Endogenous SUMO-conjugates are
immunoprecipitated from cell lysates using SUMO-specific mAbs immobilized on the beads. A buffer with low/high
pH or SDS detergent elutes both SUMO-conjugates and contaminant proteins (X, Y and Z), whereas an excess amount
of SUMO-epitope peptides specifically elute SUMO-conjugates. (B) The SUMO-1- and SUMO-2/3-epitope-peptides
specifically eluted SUMO-1- and SUMO-2/3-conjugates immunoprecipitated from 293T cell lysates, whereas 1× SDS
sample buffer (1× SSB) non-specifically eluted both SUMO-conjugates and contaminant proteins including heavy
chains (H.C.) and light chains (L.C.) of mAbs. Notes: **, free SUMO; *, SUMO-epitope peptide.

Figure 2.4. Mapping of the epitope peptide sequences of mouse mAbs specific to SUMO-1 (21C7) and SUMO2/3 (8A2). (A and C) The diagrams show the procedures for mapping the epitope peptide sequences of mAbs 21C7
(A) and 8A2 (C). The overlapping fragments of GST-tagged SUMO-1 (A) and SUMO-2 (C) were cloned using
pGEX-4T-1 vector, expressed in E. coli BL21 (DE3) cells, purified using Glutathione Sepharose 4B (GE Healthcare),
and analyzed by immunoblotting with mAbs 21C7 and 8A2 to identify the smallest fragment containing SUMO-1 or
SUMO-2 epitope peptides, respectively. The fragments containing the SUMO-1 or SUMO-2 epitope peptide are
highlighted in red or blue boxes. Following three rounds of subcloning and immunoblotting analysis, the SUMO-1
epitope peptide sequences were mapped to two overlapping fragments including B34 (13 aa) and B35 (12 aa), whereas
the SUMO-2 epitope peptide sequences were mapped to C14 (12 aa) and C15 (13 aa). (B and D) Purified GSTSUMO-1 or GST-SUMO-2 fragments were analyzed by SDS-PAGE and Coomassie blue staining. After each round
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of sub-cloning, the epitope-containing region was determined by immunoblot analysis using mAbs 21C7 (B) or 8A2
(D). After the third round, the epitope region was mapped to ~12 amino acids in length. The DNA primers for PCR
amplification of each SUMO-1 and SUMO-2 fragment are listed in Appendix A Table A.1 and A.2 .

Figure 2.5. Identification of the SUMO-1 and SUMO-2 epitope peptide sequences recognized by anti-SUMO-1
(21C7) and anti-SUMO-2/3 (8A2) mAbs. (A and E) The diagrams show the different sizes of SUMO-1 (A) and
SUMO-2 (E) fragments that can be detected by 21C7 and 8A2 mAbs in immunoblotting analyses, respectively. The
epitope peptide sequences of SUMO-1 (B34) and SUMO-2 (C14) fragments are framed by open boxes. (B and F)
The locations of SUMO-1 (B) and SUMO-2 (F) epitope peptide sequences on their corresponding 3D structures are
highlighted by the pink arrows. (C and D) The GST-SUMO-1 full-length (97 aa), B3 (21 aa), B34 (13 aa), B35 (12
aa) and B36 (10 aa) fragments were analyzed by immunoblotting with mAbs specific to SUMO-1 (21C7) and GST
(Santa Cruz) (C). The immunoblotting signals of SUMO-1 were quantified using Image J software (NIH) and then
normalized with the corresponding signals of GST (D). Compared to the other two short fragments including B35
and B36, B34 showed a relatively higher SUMO-1/GST signal ratio and thus was considered as the SUMO-1-epitope
peptide for 21C7 mAbs. (G and H) The GST-SUMO-2 full-length (93 aa), C1 (22 aa), C13 (12 aa), C14 (12 aa) and
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C16 (10 aa) fragments were analyzed by immunoblotting with mAbs specific to SUMO-2 (8A2) and GST (G). The
immunoblotting signals of SUMO-2 were normalized with those of GST (H). Compared to the other two short
fragments including C13 and C16, C14 showed a relatively higher SUMO-2/GST signal ratio and thereby was
considered as the SUMO-2-epitope peptide for 8A2 mAbs.

Notably, our sequence analyses using Jalview software(Waterhouse et al., 2009) revealed
that the SUMO-1 and SUMO-2/3 epitope peptides recognized by mAbs 21C7 and 8A2 are widely
conserved across all vertebrate species (Figure 2.6A and B). In addition, the single SUMO in D.
melanogaster contains a nearly identical sequence with just a valine (V) different from the
conserved isoleucine (I) of the SUMO-2/3-epitope peptides (Figure 2.6B). Consistent with the
result reported by Melchior and colleagues (Becker et al., 2013), 8A2 mAbs can detect endogenous
SUMO-conjugates in Drosophila S2 cells. Interestingly, we found that levels of SUMOconjugates in Drosophila S2 cells are at least three-fold higher than those of SUMO-2/3-conjugates
in human HeLa cells after normalized with α-Tubulin as a loading control for total proteins (Figure
2.6C). Furthermore, we demonstrated that the SUMO-2/3-epitope peptides can be used to elute
the endogenous SUMO-conjugates immunoprecipitated from Drosophila S2 cells by 8A2 mAbs
with high specificity and efficiency (Figure 2.6D). Therefore, these results indicated that SUMO2/3-ePIPE is broadly applicable for affinity purification of endogenous SUMO-2/3-conjugates in
all the vertebrate species as well as the single SUMO-modified proteins in certain invertebrate
species including D. melanogaster.
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Figure 2.6. The alignment of SUMO-epitope-peptide sequences among SUMO sequences of difference species
and the application of SUMO-2/3-ePIPE for purification of endogenous SUMO-conjugates in Drosophila S2
cells. (A) The SUMO-1-epitope-peptide sequence for 21C7 is conserved among vertebrate species. The SUMO-1
proteins from human (H. sapiens), mouse (M. musculus), chicken (G. gallus) and Xenopus (X. laevis) contain the
identical SUMO-1-epitope-peptide sequence, whereas the SUMO-1 protein from zebrafish (D. rerio) contains a nearly
identical sequence with only a valine (V) different from the methionine (M) conserved in other vertebrate species.
This result suggests that SUMO-1-ePIPE should be applicable for purification of endogenous SUMO-1-conjugates in
most vertebrate species. (B) The SUMO-2/3-epitope-peptide sequence for 8A2 is highly conserved among a variety
of species ranging from human to Drosophila. The SUMO-2/3 proteins from all the analyzed vertebrate species
contain the identical SUMO-2/3-epitope-peptide sequence, whereas the sole SUMO protein from the invertebrate
species D. melanogaster contains an almost identical sequence with just a valine (V) residue different from the
isoleucine (I) residue conserved among vertebrate species. This result suggests that SUMO-2/3-ePIPE should be
applicable for purification of endogenous SUMO-2/3-conjugates in most vertebrate species and certain invertebrate
species including D. melanogaster. (C) The total cell lysates from human HeLa and Drosophila S2 cells were
immunoblotted using mAbs specific to α-Tubulin and SUMO-2/3 (8A2). (D) Endogenous SUMO-conjugates in
Drosophila S2 cells were immunoprecipitated by 8A2, eluted by SUMO-2/3-epitope-peptides, and then blotted with
8A2. Arrow head indicates the heavy chains of 8A2 eluted by 2× SSB.

Lastly, we showed that SUMO-2/3-epitope peptides can be used for purification of
endogenous SUMO-2/3-conjugates in human brain tumor samples. Glioblastoma multiforme
(GBM) is the most common and lethal type of human primary brain tumor (Yang et al., 2013).
Levels of SUMO-2/3-conjugates are up-regulated about 29.0-fold in GBM samples compared to
control samples (Yang et al., 2013). Total proteins were extracted from ~100 mg of GBM samples
as described (Yang et al., 2013) and used for immunoprecipitation of SUMO-2/3-conjugates using
8A2 mAbs. Immunoprecipitated SUMO-2/3-conjugates could be specifically eluted by SUMO2/3-epitope peptides when compared to control peptide elution (Figure 2.7).
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Figure 2.7. Affinity purification of endogenous SUMO-2/3-conjugates in human glioblastoma (GBM) tumor
tissues using SUMO-2/3-ePIPE. About 100 mg of GBM tumor tissue samples were used for immunopurification of
endogenous SUMO-2/3-conjugates using anti-SUMO-2/3 mAbs (8A2) immobilized on Protein-G beads. The
immunoprecipitated SUMO-2/3-conjugates were eluted by either control or SUMO-2/3-epitope peptides. Different
percentages of control- or epitope-peptide elution products were separated by SDS-PAGE and analyzed by
immunoblotting using 8A2 mAbs (3%) (A), silver staining (15%) (B) and Coomassie blue staining (82%) (C).

2.4.3 Analysis of Changes in SUMO-2/3 Modification in Metastatic Breast
Cancer Cells
Having established SUMO-ePIPE as an efficient method for purifying endogenous SUMOconjugates, we next applied this technique to characterize the relationships between the metastatic
progression of breast cancer and the changes of SUMO-2/3 modification. We focused on
identifying the proteins differentially modified by SUMO-2/3 in metastatic 66cl4 cells compared
to non-metastatic 1F68FARN cells. To achieve this goal, we coupled SUMO-2/3-ePIPE with
SILAC-based quantitative mass spectrometry (Andersen et al., 2009; Schimmel et al., 2008;
Tatham et al., 2011; Vertegaal et al., 2006; Westman et al., 2010; Yang et al., 2012). We first
cultured 168FARN cells in light (L) medium (Arg0, Lys0) and 66cl4 cells in heavy (H) medium
(Arg10, Lys8) (Figure 2.8A). The SILAC-labeled 168FARN and 66cl4 cells (~ 3x1010 total) were
then lysed under stringent denaturing conditions including 10 mM NEM (N-ethylmaleimide) to
block de-SUMOylation mediated by SUMO-isopeptidases. The cell lysates were mixed in a 1:1

52

ratio of total proteins and then passed through a 2 ml column of Protein G beads cross-linked to
8A2 mAbs. The immunoprecipitated SUMO-2/3 conjugates were eluted by either control- or
SUMO-2/3-epitope-peptides, enriched by TCA precipitation, and analyzed by immunoblotting,
silver staining and Coomassie-blue staining (Figure 2.8B-D). Using 100 ng of His6-SUMO-2 as a
loading control, we estimated that about 2-3 μg of SUMO-2/3-conjugates were purified by SUMO2/3-ePIPE. Notably, few proteins were eluted by control peptides, indicating the high specificity
of SUMO-2/3-ePIPE in eluting SUMO-2/3 conjugates. The gel lanes corresponding to controland epitope-peptide elution were sliced and used for quantitative mass spectrometry (Figure 2.8D).

A

B

C

D

Figure 2.8. SUMO-2/3 epitope peptide elution. (A) A diagram shows that SUMO-2/3-ePIPE can be coupled with
SILAC-based quantitative mass spectrometry for identifying the proteins differentially modified by endogenous
SUMO-2/3 between non-metastatic 168FARN and metastatic 66cl4 cells. (B-D) SUMO-2/3-ePIPE was used to purify
a large quantity of endogenous SUMO-2/3-conjugates from SILAC-labeled 168FARN and 66cl4 cells for quantitative
proteomic analysis. The immunoprecipitated SUMO-2/3 conjugates were eluted using control or SUMO-2/3-epitope
peptides, analyzed by immunoblotting (B), silver staining (C), and Coomassie Blue staining (D). His6-SUMO-2
proteins (100 ng) were used as a loading control for quantification of immunopurified SUMO-2/3-conjugates (B and
C).

The nanoflow liquid chromatography-tandem mass spectrometry analyses (LC-MS/MS)
have identified 66 putative SUMO-2/3 substrates after subtracting the background from a total of
151 unique proteins (Supplementary dataset 1). Proteins identified in both SUMO-2/3-ePIPE (SE)
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and control-peptide elution (CL) samples with a SE/CL ratio less than two were eliminated.
Among the 66 putative substrates, 47 proteins were detected with a SILAC H/L ratio that
represents the relative levels of SUMO-2/3 modification on each protein between 66cl4 and
168FARN cells (Dataset 1). We analyzed the gene ontology of these 66 substrates using the
STRING program (Franceschini et al., 2013) and grouped them into seven categories based on
their primary biological functions, including gene expression (35%), metabolism (26%), cell
migration (14%), stress response (8%), cell cycle (8%), SUMO/ubiquitin pathways (6%), and
inflammation (5%) (Figure 2.9A). Using the STRING program (Franceschini et al., 2013), we
also identified six major high-confidence interaction networks within the 66 substrates, including
cell migration, translation, glycolysis, SUMO/ubiquitin pathways, cell cycle, and stress response
(Figure 2.9B).
To evaluate the quality of our proteomic analyses, we compared the above 66 SUMO-2/3
substrates with those identified by three well-recognized proteomic studies of SUMO-2/3
modification using human HeLa cells (Bruderer et al., 2011; Schimmel et al., 2008; Tatham et al.,
2011) and also with those whose SUMOylation was validated previously (Figure 2.9A and
Supplementary dataset 1 including references). We found that 50 of the 66 substrates (76%)
overlap with those identified by the three proteomic studies, whereas 22 proteins (33%) have been
formerly validated. Together, 51 substrates (77%) are classified as “Known SUMO Substrates”
based on the three previous proteomic studies and also the studies for validation of individual
substrates. Furthermore, 45 proteins (68%) have been previously implicated in cancer and thus
categorized as “Linked to Cancer”, whereas 37 proteins (56%) represent an overlap between
“Known SUMO Substrates” and “Linked to Cancer”. Lastly, we compared to the SUMO-2/3
substrates identified in this study with those identified by Melchior and colleagues using human
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HeLa cells and also a technique nearly identical to our SUMO-2/3-ePIPE (Becker et al., 2013).
We found an overlap of eight substrates between these two studies, including PML, SAE2, SUMO2/3, Trim28, H2B, RPS9, RPS16, and NUMA1. This limited overlap between these two proteomic
studies was at least partially caused by using different cells, human cervical cancer cells (HeLa)
and mouse breast cancer cells (168FARN and 66cl4).

Figure 2.9. Functional classification and interaction network analysis of the SUMO-2/3-conjugated protein
identified in metastatic and non-metastatic breast cancer cells. (A) Among the 66 SUMO-2/3 substrates, the
percentage of unique proteins in each functional category is indicated in parentheses. These proteins were classified
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into the seven functional groups. Alternatively, they were classified into three different categories, including 51
“Known SUMO Substrates”, 45 proteins “Linked to Cancer”, and 7 proteins as “Other” that have not been previously
identified as either “Known SUMO Substrates” or “Linked to Cancer”. (B) The high-confidence interaction networks
within the putative SUMO-2/3 substrates identified by SUMO-2/3-ePIPE and mass spectrometry. The above SUMO
substrates are indicated by their official gene names. The protein-protein interaction networks were obtained using
the STRING database (version 9.1) with a high-confidence level (0.700). The major interaction networks include the
SUMO-2/3-modified proteins known to play a role in cell migration, glycolysis, protein translation, cell cycle, stress
response, and SUMO/Ubiquitin pathways. The “Known SUMO Substrates” are highlighted by black circle. The
proteins with at least a 50% increase (H/L≥1.5) or decrease (H/L≤0.5) of SUMO-2/3 modification in metastatic cells
compared to non-metastatic cells were labeled in red or blue color, respectively, whereas the rest proteins are labeled
in light gray color.

Consistent with up-regulation of global SUMO-2/3 modification in 66cl4 cells compared
to 168FARN cells (Figure 2.1), our quantitative proteomic analysis revealed that the SILAC H/L
ratio of SUMO-2/3 is 2.24 between 66cl4 (H) and 168FARN (L) cells (Table 2.1 and
Supplementary dataset 1). Because free SUMO-2/3 was not detected in our SUMO-2/3-ePIPE
sample (Figure 2.8B), this H/L ratio likely represents the relative levels of SUMO-2/3-conjugates
purified from 66cl4 and 168FARN cells. In addition to the increased levels of SUMO-2/3 detected
in the immunopurified SUMO-2/3-conjugates in 66cl4 cells compared to 168FARN cells, our
quantitative proteomic analyses have also identified five proteins with more than 50% increase of
SUMO-2/3 conjugation in 66cl4 cells (H/L≥1.5), including PML (6.15-fold), MIF (2.42-fold), αEnolase (2.01-fold), Fructose-1,6-bisphosphate aldolase (Aldolase A) (1.79-fold), and eEF2
(Elongation Factor 2) (1.54-fold). These proteins are known to play a critical role in cell cycle
(PML), inflammation (MIF), glycolysis (α-Enolase and Aldolase A) and translation (eEF2) (Table
2.1). On the other hand, we also identified about ten proteins with a significant decrease of SUMO2/3 modification in 66cl4 cells compared to 168FARN cells (SILAC H/L≤0.5) (Table 2.1 and
Supplementary dataset 1). These proteins of particular interest, including Vimentin (0.34-fold),
Plectin (0.33-fold), Gelsolin (0.19-fold), and Fibronectin (0.18-fold), are involved in cell
migration.
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Table 2.1. Endogenous SUMO-2/3-Conjugated Proteins Identified with SILAC Heavy / Light
(H/L) Ratios by Quantitative Mass Spectrometry a
Inflammation
MIF+, Kininogen-1Cell Cycle
PML+, α-Tubulin, β-Tubulin
SUMO / Ub Pathways
SUMO-2/3+, Ubiquitin+, SUMO-1, SAE2
Stress Response
-

Murinoglobulin , Hsp70, Hsp90β, Cyclophilin A, SOD1,
Cell Migration
-

-

-

Plectin , Vimentin , Gelsolin , Fibronectin-, Actin, α-Actinin, Annexin A2, Myosin-9, RhoGDI1
Metabolism
Glycolysis

ATP synthesis

Amino Acid

Copper / Iron

Lipid

α-Enolase+,
Aldolase A+,
PKM2, LDH

ATP synthase α
and β subunits

Aspartate
aminotransferase,
Phosphoglycerate
dehydrogenase

Ceruloplasmin-,
Transferrin-

Apolipoprotein
A-

Gene Expression
Transcription
Trim28/KAP1, Lamin-A/C,
Histone H2B, H3 and H4

RNA Processing
hnRNP U-, RBM12

Translation
+

eEF2 , eIF4G1, RPL8,
RPS16, RPS18, RPS26

a

The proteins with a significant increased or decreased SUMO-2/3 modification in metastatic cells
(H) compared to non-metastatic cells (L) are marked by “+” (H/L≥1.50) or “-” (H/L≤ 0.50).

2.4.4 Validating Putative SUMO-2/3 Substrates by in vitro SUMOylation
Assays and Confirming Changes of SUMO-2/3 Modification of Individual
Substrates in Metastatic Cells
To verify the proteomic analysis, we first used the well-established bacterial SUMOylation
assays (Uchimura et al., 2004) to test whether the selected SUMO-2/3 substrates, including MIF,
α-Enolase, Actinin-4, RhoGDI and Gelsolin, can efficiently modified in vitro. These proteins were
expressed as GST-tagged fusion proteins in the presence or absence of SUMO-2, SUMO-E1 and
Ubc9 in E. coli BL21 cells (Figure 2.10C-G). The GST and GST-tagged PML (a well-established
SUMO substrate) were used as negative and positive control, respectively (Figure 2.10A and B).
We found that all six GST-tagged fusion proteins but not GST were efficiently modified by
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SUMO-2 (Figure 2.10A-G). Further, we demonstrated that Vimentin as well as the conserved
motor domain of Myosin-12 were efficiently modified by SUMO-1 and SUMO-2 in vitro by using
recombinant E1, Ubc9 and SUMO-1 or SUMO-2 (Figure 2.10H and J). Because the motor domain
is highly conserved among the Myosin family members (Mermall et al., 1998), this result suggests
that various Myosin members, including Myosin-9, which was identified as a putative SUMO-2/3conjugated substrate in this study, might be modified by SUMOs within their conserved motor
domains.

Consistent with this idea, both Myosin-9 and Myosin-12 contain at least one

SUMOylation consensus motif with a high score (≥0.85) predicted by the SUMOplot Analysis
Program (Abgent) (Figure 2.10I).

Figure 2.10. Validation of SUMO substrates by in vitro SUMOylation assays. (A-G) Bacterial SUMOylation
assays were used to validate five SUMO-2/3 substrates including GST-tagged MIF (C), α-Enolase (D), Actinin-4 (E),
RhoGDI (F) and Gelsolin (G), while GST (A) and GST-tagged PML (B) were used as negative and positive controls,
respectively. The purified GST or GST-tagged proteins were analyzed by immunoblotting with antibodies specific to
GST and SUMO-2. (H) GST-tagged Vimentin was incubated with recombinant SUMO-E1 and Ubc9 in the presence
or absence of SUMO-1 or SUMO-2, and analyzed by immunoblotting with anti-GST antibodies. (I) The SUMOplot
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Analysis Program (Abgent) was used to predict the SUMOylation consensus motif (ΨKxE/D) within the conserved
motor domains of human Myosin family members, including Myosin-9 (1960 aa) (UniProt: P35579) and Myosin-12
(1855 aa) (UniProt: Q9Y4I1)(Mermall et al., 1998). The three lysine residues (K228, K289 and K355) within the
Myosin-9 motor domain (77-775 aa) as well as the lysine residue (K471) within the Myosin-12 motor domain have
the highest SUMOplot scores and are thereby marked in bold and also underlined. (F) The purified recombinant
FLAG-tagged Myosin-12 motor domain was incubated with recombinant SUMO-E1 and Ubc9 in the presence or
absence of SUMO-1 or SUMO-2 and analyzed by immunoblotting with mAbs specific to FLAG.

Our quantitative proteomic analysis revealed that SUMO-2/3 modification of PML (6.15fold), MIF (2.42-fold), α-Enolase (2.01-fold), Pyruvate kinase M2 (PKM2) (1.37-fold), hnRNP U
(0.49-fold) was significantly up- or down-regulated in 66cl4 cells compared to 168FARN cells.
To confirm the changes of SUMO-2/3 modification of these substrates in 66cl4 cells, we
immunopurified SUMO-2/3 conjugates from 168FARN and 66cl4 cells, respectively, and then
immunoblotted with antibodies specific to α-Tubulin, SUMO-2/3, MIF, α-Enolase, PKM2, hnRNP
U and PML (Figure 2.11A-F).

Consistent with our quantitative mass spectroemtry result,

immunoblotting analysis demonstrated that SUMO-2/3 modification of MIF, α-Enolase, PKM2
and PML was at least two to six times higher in 66cl4 cells than in 168FARN cells (Figure 2.11BD and F). Although our quantitative mass spectroemtry result suggested a decrease of SUMO-2/3
modification of hnRNP U in 66cl4 cells, immunoblotting analysis of two independently
immunopurified SUMO-2/3 conjugates has reproducibly shown that SUMO-2/3 modification of
hnRNP U was about three times higher in 66cl4 cells than in 168FARN cells (Figure 2.11E).
Unmodified MIF was observed as a 15 kDa band, whereas SUMO-2/3-modified MIF was detected
as a smear from 30 to 45 kDa, indicating that MIF could be modified by one to three SUMO-2/3
moieties (Figure 2.11B). Furthermore, unmodified α-Enolase and PKM2 were found with the
corresponding sizes of 45 and 58 kDa, while their SUMO-2/3-modified forms were observed as a
high-molecular-weight smear and also as distinct bands ranging from 60 to 200 kDa and from 72
to 180 kDa respectively, suggesting that both substrates were modified at multiple sites and/or by
poly-SUMO-2/3-chains (Figure 2.11C and D). Moreover, unmodified hnRNP U was detected as
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a ~120 kDa band, whereas SUMO-2/3-modified hnRNP U was observed as a major band of ~200
kDa, suggesting that hnRNP U could be simultaneously modified by a fixed number of SUMO2/3 moieties. Consistent with this, mouse hnRNP U (NP_058085.2) contains seven SUMOylation
consensus motifs with high scores (0.61 to 0.91) predicted by the SUMOplot Analysis Program
(Abgent). Lastly, three isoforms of unmodified PML were found to be around 65, 75 and 90 kDa
in 66cl4 cells, whereas its SUMO-2/3-modified forms were detected as a high-molecular-weight
smear from ~117 to >201 kDa, suggesting that multiple SUMO-2/3 moieties were conjugated to
PML at different sites and/or as poly-SUMO-2/3-chains (Figure 2.11F). Consistent with this idea,
endogenous poly-SUMO-chain-modified PML was also detected in HeLa cells (Bruderer et al.,
2011).
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Figure 2.11. Verifying the changes of SUMO-2/3 modification of individual substrates in metastatic cells and
investigating the effects of SUMO-23 modification on PML-NB assembly and 3-D cell migration. (A-F) SUMO2/3 conjugates were immunoprecipitated from 168FRAN and 66cl4 cells, eluted by either control or SUMO-2/3epitope peptides, and analyzed by immunoblotting using antibodies specific to SUMO-2/3 (A), MIF (B), α-Enolase
(C), PKM2 (D), hnRNP U (E), and PML (F). The arrows indicate unmodified proteins (B-F). (G) Cells were double
labeled with rabbit anti-PML (red) and mouse anti-SUMO-2/3 (green) antibodies and analyzed by indirect
immunofluorescence microscopy. Bar equals 5 μm. (H) The number of PML-NBs was significantly higher in 66cl4
cells (5.45/cell) than in 168FARN cells (2.75/cell). We randomly selected 100 cells from each of the two lines,
168FARN and 66cl4, and counted all the PML-NBs in each cell under Olympus inverted IX81 fluorescence
microscope using Z-stacks. The number of PML-NBs in each cell for all the analyzed cells was included in
Supplementary dataset 1. Each column represents the mean value ± SEM (N = 100, *P = 6.5x10-24, Student’s t test).
(I) Overexpression of GFP-SUMO-2/3 in 168FARN cells increases the linear speed (μm/min) of 3D cell migration
within a collagen gel. Each bar represents the mean value ± SEM from 10 sets of time-lapse microscopy videos of
168FARN cells expressing GFP or GFP-SUMO-2/3 proteins (N = 10, *P = 3.0 × 10-6, Student’s t test).
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2.4.5 Functional Analyses of Enhanced PML and Global SUMO-2/3
Modification on PML-NB Assembly and 3D Cell Migration
It has been shown previously that both SUMO-modification of PML and its SUMObinding activities are required for the assembly of PML nuclear bodies (PML-NBs) (Shen et al.,
2006b). To test if up-regulation of SUMO-2/3 modification of PML increases the formation of
PML-NBs in 66cl4 cells, we compared the number of PML-NBs between 168FARN and 66cl4
cells by immunofluorescence microscopy using antibodies specific to PML and SUMO-2/3
(Figure 2.11G).

Consistent with our hypothesis, the average number of PML-NBs was

significantly higher in 66cl4 cells (5.45/cell) than in 168FARN cells (2.75/cell) (Figure 2.11H).
A previous study has shown that the linear speed of 3D cell migration of metastatic 66cl4
cells is higher than that of non-metastatic 168FARN cells (Indra et al., 2011), which is positively
correlated to the up-regulation of SUMO-23 modification in 66cl4 cells compared to 168FARN
cells (Figure 2.1). Furthermore, our proteomic analysis of changes in SUMO-2/3 modification
between 66cl4 and 168FARN cells has revealed a list of putative SUMO substrates involved in
cell migration (Table 2.1), suggesting that perturbations of SUMO-2/3 modification may affect
cell migration. To test whether up-regulation of global SUMO-2/3 modification contributes to
breast cancer metastasis by promoting cell migration (Indra et al., 2011), we overexpressed both
GFP-tagged SUMO-2 and SUMO-3 fusion proteins in non-metastatic 168FARN cells.
Overexpression of GFP-SUMO-2/3 is known to increase global SUMO-2/3 modification in human
HeLa cells (Ayaydin and Dasso, 2004). Consistent with our hypothesis, we found that
overexpression of GFP-SUMO-2/3 in 168FARN cells leads to a two-fold increase of 3D migration
speed compared to control cells overexpressing GFP (Figure 2.11I).
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Figure 2.12 Overexpression of GFP-tagged SUMO-2/3 wild-type or non-conjugatable mutants increases 3D cell
migration. (A) 293T cells were transfected with either GFP empty vector or plasmids encoding GFP-SUMO-2, GFPSUMO-3 or GFP-SUMO-2/3 wild-type (WT) and also their corresponding non-conjugatable mutants. Site-directed
mutagenesis was used to mutate the DNA sequences encoding the glycine-glycine (GG) residues at the C-terminal
end of mature SUMO-2 and SUMO-3 WT to those encoding alanine-alanine (AA) residues of non-conjugatable
mutants. The transfected cells were lysed in 2× SSB and analyzed by immunoblotting with antibodies specific to GFP
and α-Tubulin. (B) Overexpression of GFP-SUMO-2/3 (GFP-S2/3) WT or their non-conjugatable mutants in
168FARN cells increases the linear speed (μm/min) of 3D cell migration within a collagen gel. Each bar represents
the mean value ± SEM from 10 sets of time-lapse microscopy videos of 168FARN cells expressing GFP, GFP-S2/3
WT, or GFP-S2/3 Mutant (N = 10, P < 0.0001, Student’s t test).

Futhermore, we tested whether the increase of 3D cell migration mediated by
overexpression of GFP-SUMO-2/3 is definitely dependent on the conjugation activity of GFPSUMO-2/3. Interestingly, we found that overexpression of either GFP-SUMO-2/3 wild-type (WT)
or non-conjugatable mutant significantly increased 3D cell migration (Figure 2.12), suggesting
that free SUMO-2/3 somehow could also promote cell migration. Consistent with this idea, levels
of both high-molecular weight SUMO-2/3 conjugates and unconjugated SUMO-2/3 in 66cl4 are
higher than in 168FARN cells (Figure 2.1).

63

Figure 2.13 A model elucidates that dysregulation of SUMOylation might contribute to breast cancer
progression and metastasis by affecting multiple cellular processes, including cell migration, cell cycle,
inflammation, glycolysis, SUMO/ubiquitin pathway, and gene expression.

2.5 DISCUSSION
Most recent proteomic studies of SUMOylation often involve the development of stably
transfected cells expressing affinity-tagged-SUMO variants (Schimmel et al., 2008; Tatham et al.,
2011; Vertegaal et al., 2004). The expression of tagged-SUMO over the background of
endogenous SUMOs likely affects many processes critical for cancer. Clearly, the lack of an
effective strategy to identify the targets differentially modified by endogenous SUMO between
cells at different stages of cancer has obstructed the progression toward elucidating how
SUMOylation affects cancer progression and metastasis. In this study, we established a proteomic
method by coupling SUMO-2/3-ePIPE with SILAC-based quantitative mass spectrometry for
analysis of the changes in SUMO-2/3 modification between metastatic and non-metastatic cells.
Using this method, we identified 66 putative SUMO-2/3 targets, in which at least 15 proteins
exhibit a significant increase/decrease of SUMO-2/3 modification in metastatic 66cl4 cells when
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compared non-metastatic 168FARN cells. Furthermore, we validated the increase of SUMO-2/3
modification of PML, MIF, α-Enolase and PKM2 in 66cl4 cells compared to 168FARN cells
(Figure 2.11). Clearly, our results demonstrated that this proteomic method is a very useful tool
for identifying the proteins whose SUMO-modification is different or altered between two
biological samples of particular interest. These samples could be originated from various sources
ranging from human to Drosophila and from cultured cells to tissue samples. Moreover, our
immunofluorescence microscopy analysis indicated that up-regulation of SUMO-2/3 modification
of PML is associated with an increased number of PML-NBs in 66cl4 cells compared to 168FARN
cells (Figure 2.11G and H), suggesting that the increase of SUMO-2/3 modification of PML may
promote the assembly of PML-NBs in 66cl4 cells. Consistent with this idea, the massive increase
of SUMOylation triggered by hypothermia stress is known to elevate the assembly of PML-NBs
in both number and size (Lee et al., 2007). Although PML has been regarded as a tumor suppressor,
recent studies have revealed that PML can also play a pro-survival role and its overexpression is
associated with a subset of triple-negative breast cancers (Carracedo et al., 2012). Hence, it is
possible that up-regulation of PML SUMO-2/3-modification and PML-NB assembly may
contribute to the increased metastatic capacity of 66cl4 cells compared to 168FARN cells.
Notably, we have identified and confirmed MIF as a novel SUMO substrate both in vitro and in
vivo. As a key pro-inflammatory cytokine and breast cancer marker, MIF represents a direct link
between inflammation and cancer by contributing to a microenvironment that favors cancer growth
and progression (Conroy et al., 2010; Grieb et al., 2010; Simpson et al., 2012; Verjans et al., 2009).
Therefore, it would be very interesting to explore whether up-regulation of SUMO-2/3
modification of MIF plays a role in breast cancer progression and metastasis.
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Similar to ubiquitination, SUMO-2/3 modification is up-regulated in response to various
types of stress and thus serves as an important mechanism to protect cells from stress-induced cell
death or apoptosis (Guo et al., 2013; Saitoh and Hinchey, 2000). Furthermore, up-regulation of
SUMOylation has been frequently observed in cancers with poor prognosis (Bawa-Khalfe and
Yeh, 2010; Kessler et al., 2012; Kim and Baek, 2006). Hence, it is possible that compared to nonmetastatic cells, up-regulation of SUMO-2/3 modification in metastatic cells may presumably
increase the capacity of these cells in response to various types of stress and protect them from
stress-induced death so that they are capable to migrate, survive, proliferate and form secondary
tumors at distal organ(s). Consistent with this idea, we found that SUMO-2/3 modification of
eEF2, an essential factor for protein synthesis, was up-regulated more than 50% in 66cl4 cells than
in 168FARN cells. SUMOylation of eEF2 is not only involved in drug resistance in lung
carcinoma cells but also critical for its stability and anti-apoptotic activity (Chen et al., 2011). In
addition, we found that levels of ubiquitin (1.5-fold) covalently associated with the
immunopurified SUMO-2/3-conjugates in 66cl4 cells are 50% higher than those in 168FARN
cells, which is positively correlated to the increase of SUMO-2/3 modification in 66cl4 cells. This
positive correlation likely reflects the tight link between ubiquitination and polymeric SUMO-2/3
modification, since it is known that poly-SUMO-2/3-chains can be recognized by the SUMOtargeted ubiquitin ligase (STUbL), RNF4, leading to ubiquitination of poly-SUMO-2/3-chainmodified proteins (Tatham et al., 2008; Tatham et al., 2011).
Although up-regulation of Ubc9 expression is known to increase global SUMOylation and
also promote cancer cell proliferation, invasion and metastasis, (Kim et al., 2006; Mo et al., 2005)
we did not detect any obvious change of Ubc9 expression among these four breast cancer cell lines
(Figure 2.1). On the other hand, our quantitative proteomic analysis has shown that SUMO-2/3
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modification of SAE2, one of the SUMO-E1 subunits, is ~43% lower in 66cl4 cells than in
168FARN cells (Supplementary Dataset 1). Since SUMOylation of SAE2 can significantly reduce
SUMOylation by inhibiting the transfer of SUMO from E1 to Ubc9 (Truong et al., 2012), the
decrease of SUMO-2/3 conjugation to SAE2 may partially contribute to the increase of global
SUMO-2/3 modification in 66cl4 cells.
Interestingly, our proteomic analyses have revealed a network of nine SUMO-2/3
substrates critical for cell migration (Table 2.1). We have successfully validated five of them,
including α-Actinin-4, RhoGDI, Vimentin, Myosin-9 and Gelsolin by in vitro SUMOylation
assays. Our proteomic analysis revealed that SUMO-2/3 modification of RhoGDI is about 32%
lower in 66cl4 cells than in 168FARN cells (Supplementary Dataset 1). Because SUMOylation
of RhoGDI is known to inhibit cell migration (Yu et al., 2012), the decreased SUMO-2/3
modification of RhoGDI in 66cl4 cells may partially contribute to the increased speed of 3D cell
migration of these cells compared to 168FARN cells (Indra et al., 2011). Clearly, the decrease of
SUMO-2/3 modification of several proteins in 66cl4 cells when compared to 168FARN cells,
including RhoGDI, Gelsolin and Vimentin, is in contrast to the increase of global SUMO-2/3
modification in 66cl4 cells. This indicated that up-regulation of global SUMO-2/3 modification
reflects a combination of both increase and decrease of SUMO-2/3 modification of all individual
substrates in 66cl4 cells. Consistent with the previous finding that the increase of global
SUMOylation promotes cell migration and invasion (Kim et al., 2006), here we showed that upregulation of global SUMO-2/3 modification by overexpressing GFP-SUMO-2/3 can also lead to
a significant increase of 3D cell migration (Figure 2.11I). Since SUMOylation of Rac1 can
increase its ability to stimulate lamellipodia formation, cell migration and invasion (Castillo-Lluva
et al., 2010), it would be very interesting to investigate if SUMO-2/3 modification of Rac1 is up-
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regulated in 66cl4 cells when compared to 168FARN cells.

Interestingly, we found that

overexpression of non-conjugatable GFP-SUMO-2/3 mutant also significantly increased 3D cell
migration (Figure 2.12), suggesting that free SUMO-2/3 can also promote cell migration through
unkown mechanism(s) independent of their conjugation activities.

Overexpression of non-

conjugatable GFP-SUMO-2/3 mutants might indirectly affect SUMOylation of certain substrates
critical for cell migration and/or competitively inhibit the interaction of these SUMOylated
substrates with their binding proteins containing SUMO-interacting motif (SIM), leading to an
increase of 3D migration.
A nearly-universal property of cancer cells is up-regulation of glycolysis even under
aerobic conditions, a phenomenon known as Warburg effect, which promotes both proliferation
and invasion (Gatenby and Gillies, 2004). We have identified a group of enzymes involved in
glycolysis as SUMO-2/3 substrates including α-Enolase, PKM2, Aldolase A, and Lactate
dehydrogenase (LDH) (Table 2.1 and Figure 2.9B). All the enzymes were also found as SUMO2/3 targets by the three proteomic studies of SUMO-2/3 modification in HeLa cells (Bruderer et
al., 2011; Schimmel et al., 2008; Tatham et al., 2011), and their activity and expression are
significantly higher in breast cancer metastases compared to the primary tumors (Fantin et al.,
2006; Hennipman et al., 1988; Radenkovic et al., 2012). Intriguingly, levels of SUMO-2/3
modification on all the enzymes are up-regulated in 66cl4 cells compared to 168FARN cells
(Supplementary Dataset 1). Studies in yeast revealed that hypoxia stimulates SUMOylation of
several key glycolytic enzymes, including α-Enolase, Pyruvate kinase, and Aldolase A (Agbor et
al., 2010). Furthermore, up-regulation of global SUMOylation by overexpressing His-SUMO-1
in mouse embryonic fibroblast cells greatly increases glycolysis under normoxic conditions
(Agbor et al., 2010). Hence, the increase of SUMO-2/3 modification on multiple glycolytic
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enzymes could stimulate glycolysis in 66cl4 cells and thus contribute to the increased metastatic
capacity of these cells compared to 168FARN cells.
Compared to the metastatic 66cl4 cells, the non-metastatic 168FARN cells do not have the
capacities to exit the lymphatic vessels as well as to establish the secondary tumors. Hence, the
changes in SUMO-2/3 modification of these identified target proteins in 66cl4 cells compared to
168FARN cells might contribute to the metastatic capacity of 66cl4 cells by promoting their
extravasation and metastatic growth in lung. Given the expected effect of host tissue environment
on SUMOylation profiles of tumor cells, it would be ideal to perform quantitative proteomic
analyses of SUMO-2/3 modification between the two mammary tumors formed by injection of
66cl4 and 168FARN cells into the mammary glands of BALB/c mice, respectively, instead of
using these two cell lines cultured in vitro. Since SUMO-2/3-ePIPE can be used for affinity
purification of endogenous SUMO-2/3 conjugates in human GBM tumor samples, this approach
can be combined with the isobaric tag for relative and absolute quantification (iTRAQ) method
and quantitative mass spectrometry analysis (Casado-Vela et al., 2010; Kocher et al., 2009; Miller
et al., 2013) to identify the proteins differentially modified by SUMO-2/3 between two mammary
tumor samples with different metastatic capacities.
Our findings not only provide important information but also establish a very useful
method for further investigation of how perturbations of SUMOylation affect cancer progression
and metastasis. Up-regulation of global SUMO-2/3 modification in breast cancer cells may
increase the metastatic capacities of these cells by altering multiple cellular processes including
glycolysis, cell migration, cell cycle, stress response, inflammation, gene expression, and
SUMO/ubiquitin pathways (Figure 2.13).

Interestingly, levels of SUMO-1 modification in

metastatic 66cl4 cells are significantly lower than those in the three non-metastatic cells, including
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67NR, 168FARN and 4TO7 (Figure 2.1). The decrease of SUMO-1 modification in metastatic
66cl4 cells may also contribute to their increased metastatic capacity. To understand the roles of
SUMO-1 modification in breast cancer metastasis, we can apply a similar proteomic approach by
coupling SUMO-1-ePIPE with SILAC-based quantitative mass spectrometry to identify the
substrates with changes of SUMO-1 modification between metastatic and non-metastatic cells.
Although the molecular details of how SUMOylation affects cancer progression and metastasis
are still not well understood, accumulating lines of evidence have revealed that targeting the
SUMO pathway may have therapeutic efficacy for human cancers, especially for types of cancers
driven by Myc or Ras oncogene (Kessler et al., 2012; Luo et al., 2009).
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CHAPTER 3 POLYMERIC SUMO-2/3 CHAINS AT
KINETOCHORES IS ESSENTIAL FOR CHROMOSOME
ALIGNMENT BY RECRUITING CENP-E TO KINETOCHORES
3.1 ABSTRACT
Cell cycle progression through mitosis involves several post-translational modifications
including phosphorylation, acetylation, ubiquitination, SUMOylation and detyrosination. A
number of evidences have indicated the direct role of SUMO modification in precise chromosome
alignment and segregation. Inhibition of global SUMOylation either by over-expression of SENP2
or by depletion of Ubc9 results in a prometaphase arrest and disappearance of Centromere Protein
E (CENP-E) from kinetochores in mammalian cells. This led us to propose that CENP-E is
recruited to kinetochores by binding to SUMO-modified kinetochore interactors (Nuf2) through
CENP-E’s SUMO-Interacting Motif. We have shown that Nuf2 is crucial for CENP-E localization
to kinetochores and is modified by polymeric SUMO-2/3 chains at multiple lysine residues. In
support of the above proposition, we have demonstrated that trimeric SUMO-2 chain fused to the
C-terminus of Nuf2 rescues the prometaphase arrest and CENP-E mislocalization caused by
SENP2 overexpression. However, monomeric or dimeric SUMO-2 or trimeric SUMO-1 chain
fused to Nuf2 does not rescue the mitotic defects caused by inhibition of SUMOylation.
Furthermore, we demonstrate that compared to Nuf2 alone, the trimeric SUMO-2 and Nuf2 fusion
protein has a higher binding affinity to CENP-E wild-type but not its SUMO Interacting Motif
(SIM) mutant.

3.2 INTRODUCTION
SUMOylation is an essential post translational modification involved in many processes,
such as DNA repair, nuclear transport, cell cycle progression, and stress response (Flotho and
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Melchior, 2013; Hay, 2005). SUMO-2/3 can form polymeric chains in vivo (Tatham et al., 2001),
but SUMO-1 appears to be a chain terminator on SUMO-2/3 chains in vivo (Matic et al., 2008).
Although about 75% of targets get SUMO modified within the SUMO consensus site (Ψ-K-XD/E) (Sampson et al., 2001), SUMO modification can also occur at non-consensus site (Yang et
al., 2011).
Several studies have indicated the role of SUMO modification in chromosome alignment
and segregation during mitosis (Dasso, 2008; Wan et al., 2012b). Interestingly, it has been reported
that SUMO-1, concentrated in the spindle pole and spindle midzone and SUMO-2/3, contained to
the mitotic chromosome, clearly have unique localization during mitosis. Smt3 (yeast SUMO)
polymeric chains are shown to be essential for chromosome segregation (Srikumar et al., 2013).
There are at least ten proteins in the centromere/kinetochore region that are identified as SUMO
targets during mitosis in various organisms ranging from yeast to humans, many of them being
specifically modified by SUMO-2/3 (Wan et al., 2012b). Furthermore, Ubc9 and the E3 ligases
PIAS3 and PIASy are localized on the kinetochores during mitosis (Agostinho et al., 2008; Ban et
al., 2011; Joseph et al., 2004). Earlier studies have shown that depletion of yeast Ubc9 results in
chromosome segregation defects (Seufert et al., 1995). In mammalian cells, depletion of SENP6
lead to mitotic defects and degradation of Centromere Protein I (Mukhopadhyay et al., 2010).
One of the important proteins for chromosome congression to the metaphase plates, CENPE, is SUMO-2/3 modified both in vitro and in vivo (Zhang et al., 2008). CENP-E is a plus end
directed kinesin-7 family protein with an N-terminal microtubule binding motor domain, a coiledcoil domain and a C-terminal kinetochore binding domain. During G2 phase of the cell cycle, this
kinesin like protein is accumulated and found in the cytosol (Yen et al., 1992). However, during
mitosis it is found on the outer kinetochores from prophase through metaphase, and is localized to
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the spindle midzone during anaphase (Cooke et al., 1997; Yen et al., 1991). As CENP-E is essential
for stable kinetochore microtubule attachments, human cells with depletion of CENP-E are
arrested in prometaphase (Putkey et al., 2002; Schaar et al., 1997). Furthermore, anti-CENP-E
small molecule inhibitors like UA62784 and GSK923295A exhibit anti-tumor activity (Henderson
et al., 2009; Wood et al., 2010). The SUMO Interacting Motif found on CENP-E is required for
its kinetochore localization and CENP-E specifically binds to polymeric SUMO-2/3 chains (Zhang
et al., 2008).
Of the various kinetochore proteins, Nuf2 (Liu et al., 2007), BubR1 and CENP-F (Chan et
al., 1998) are known to interact with CENP-E. Nuf2 is part of a dumb-bell shaped tetrameric
complex along with Hec1/Ndc80, Spc24 and Spc25. The C-termini of Spc24 and Spc25 are
towards the kinetochore, whereas the N-termini of Spc24 and Spc25 interact with the C-termini of
Nuf2 and Hec1, respectively. The N-termini of Nuf2 and Hec1 face the plus ends of the
microtubules. Nuf2, localized to the outer kinetochore during all phases of mitosis (Hori et al.,
2003), is crucial for stable microtubule-kinetochore attachments and chromosome congression on
to metaphase plates (Chan et al., 1998; McCleland et al., 2003). Depletion of Nuf2 leads to
prolonged mitotic arrest and eventually apoptosis (DeLuca et al., 2002). Additionally, Nuf2 is
specifically modified by SUMO-2/3 in vivo (Zhang et al., 2008).
Recent studies in mammalian cells have shown that depletion of SUMO-2/3 from the
centromere by either over-expressing SENP2 or by depleting Ubc9 resulted in a prometaphase
arrest and a mislocalization of CENP-E from the kinetochores (Zhang et al., 2008). How does
inhibition of SUMOylation lead to disappearance of CENP-E from kinetochores remains an open
question. We hypothesized that SUMO modification of one/more of the CENP-E interacting
protein/s (Nuf2 and/or BubR1) is/are SUMO modified which is important for recruiting CENP-E
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through its SIM. In order to test this hypothesis, we generated various FLAG-tagged Nuf2
constructs encoding FLAG-Nuf2 (negative control), FLAG-Nuf2-SUMO-2, FLAG-Nuf22xSUMO-2, FLAG-Nuf2-3xSUMO-2, FLAG-Nuf2-Ubc9 (WT), FLAG-Nuf2-Ubc9 (C93A) and
FLAG-Nuf2-3xSUMO-1 fusion constructs. Consistent with our hypothesis, overexpression of
FLAG-Nuf2-3xSUMO-2 and FLAG-Nuf2-Ubc9 (WT) but not the other FLAG-Nuf2 fusion
proteins rescued the defect in chromosome alignment to metaphase plates by recruiting CENP-E
to kinetochores in cells with SENP2 overexpression. Furthermore, we observed that the Nuf23xSUMO-2 has higher binding affinity to CENP-E compared to Nuf2. In this chapter, I have
demonstrated the molecular mechanism by which CENP-E is recruited to kinetochores by means
of SUMO modification of CENP-E-interacting proteins in the kinetochore region.

3.3 MATERIALS AND METHODS
Plasmids, Antibodies and siRNA oligos:
The pFLAG-Nuf2 construct was generated by cloning Nuf2 in between ClaI and BamHI
sites of pFLAG-CMV vector. The pFLAG-Nuf2-3xSUMO-1, pFLAG-Nuf2-3xSUMO-2 and
pFLAG-Nuf2-Ubc9(WT) plasmids were created by sub-cloning 3xSUMO-1, 3xSUMO-2 and
Ubc9(WT) between BamHI and SmaI to the C-terminus of Nuf2 in pFLAG-Nuf2. Constructs
containing 3xSUMO-1 and 3xSUMO-2 were a kind gift from Dr. Michael Matunis’s lab. pFLAGNuf2-Ubc9 (C93A) was generated by performing a site-directed mutagenesis to convert Cys93 to
Ala in the pFLAG-Nuf2-Ubc9 (WT) construct. pFLAG-Nuf2-SUMO-2 was constructed by
subcloning Nuf2-SUMO-2 from pFLAG-Nuf2-3xSUMO-2 vector between ClaI and XbaI in
pFLAG-CMV vector. pFLAG-Nuf2-2xSUMO-2 were constructed by creating a stop codon at the
end of the second SUMO-2 of pFLAG-Nuf2-3xSUMO-2 by site-directed mutagenesis. For in vitro
binding assay, Nuf2 and Nuf2-3xSUMO-2 were cloned in to pGEX6p-1 between SmaI and SalI
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sites. pGEX6p-1-Nuf2 (6K/R) used for in vitro SUMOylation assays was obtained by performing
site directed mutagenesis using pGEX6p-1-Nuf2 (WT) as template. The primers used for cloning
for all the above constructs are listed in Appendix B Table B.1. Primers used for mutagenesis are
listed in Appendix B Table B.2. Antibodies used in the chapter are recorded in Appendix B Table
B.3. Finally, Appendix B Table B.4 contains the siRNA oligos used in this study.

Cell culture and transfections:
Human cervical cancer HeLa cells and Human Embryonic Kidney (HEK) 293T cells were
cultured in DMEM media (HyClone) with 1% Penicillin-Streptomycin and enhanced with 10%
Fetal Bovine Serum. HeLa cells were transfected with oligos and plasmids using oligofectamine
and lipofectamine (Invitrogen) respectively; whereas HEK 293T cells were transfected with
plasmids using CaCl2.

Immunofluorescence microscopy:
HeLa cells were grown to 70% confluency on coverslips. After transfection, cells were
fixed with 3.5% paraformaldehyde for 7 min and permeabilized with 0.02% Triton-X-100 for 20
min. The fixed cells were incubated with primary antibodies (Appendix B Table B.3) for one hour,
secondary antibodies for half an hour, mounted on glass slides and observed using Olympus
inverted 1X81 florescence microscope.

Quantification:
For experiments involving knockdown of Nuf2 (Figure 3.1), mitotic cells without CENPE were manually counted (Figure 3.1C). Mitotic cells were classified into Pro (Prophase and
Prometaphase), Met (Metaphase) and Ana/Tel (Anaphase/Telophase) based on DAPI staining.
Mitotic index is the number of mitotic cells over the total number of cells (Figure 3.1D). To
quantify cells for chromosome alignment (Figures 3.2E, 3.4D and 3.5D), mitotic cells transfected
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with both Myc-SENP2 and one of the FLAG-Nuf2 constructs were counted manually and was
classified under one of the mitotic stages depending on their DAPI stain. For CENP-E localization
(Figures 3.2G, 3.4F and 3.5F), mitotic cells transfected with Myc-SENP2 were manually counted.
The mitotic stages of the cells were determined by DAPI stain of chromosome DNA. These
experiments were repeated at least three times by counting 100 mitotic cells each time.
For cells treated with Ubc9 siRNA oligos and then transfected with FLAG-Nuf2 or FLAGNuf2-3xSUMO-2, quantification for CENP-E localization was done as follows. Percentage of
mitotic cells with obvious CENP-E staining without FLAG signals were subtracted from the
percentage of mitotic cells with CENP-E staining with FLAG signals. This difference in the
percentage was plotted in the Y-axis.

In vitro binding assay:
GST-Nuf2 and GST-Nuf2-3xSUMO-2 coding sequences were cloned into pGEX-6P-1
and transformed into BL21 DE3 cells. The cells were grown till they reached OD 0.6 and then
induced with IPTG at a final concentration of 400 µM overnight at 4oC. The induced GST-tagged
proteins were then purified using Glutathione sepharose beads (GE healthcare). FLAG-CENP-E
tail domain WT and its SIM mutant were transfected into HEK293T cells. The transfected cells
were then lysed in lysis buffer (5omM Tris HCl pH-7.5, 0.2% NP-40, 10% Glycerol, 2 mM EDTA,
25 mM NaF, 50 mM NaCl, 10 mM NEM, 1 mM Aprotonin, 1 mM LAP and 1 mM PMSF). The
whole cell lysates were then incubated with either GST-Nuf2 or GST-Nuf2-3xSUMO-2
immobilized to Glutathione beads in binding buffer, which is the same as lysis buffer except that
the concentration of NP-40 is 0.02%. After five hours, the beads were washed six times with wash
buffer (50 mM Tris HCl pH-7.5, 0.02% NP-40, 10% Glycerol, 2 mM EDTA and 50 mM NaCl).
The bound CENP-E was eluted with 2x SDS Sample Buffer (2x SSB) and analyzed by
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immunoblotting with anti-GST and anti-FLAG antibodies. The quantification was done using
Image J software.

In vitro SUMOylation:
GST-Nuf2 was purified as described in the previous section. Nuf2 was then cleaved from
the GST tag using PreScission Protease. Purified Nuf2 or GST-RanGAP1 (NΔ419) was incubated
with E1 activating enzyme (0.5µg), E2 conjugating enzyme (0.3µg), along with the ATP
regenerating system in the presence or absence of SUMO-1 (WT), SUMO-1 (K-less) or SUMO-2
(1 µg) for the indicated times at 37oC. The samples were run on an SDS-PAGE, and a Western
blot analysis was performed using anti-Nuf2 to detect SUMO-modified Nuf2 or anti-GST
antibodies to detect SUMO-modified-GST-RanGAP1 (NΔ419).

Immunoprecipitation:
HEK293T cells were transfected with FLAG-Nuf2 using CaCl2. 48 hours after transfection,
cells were treated with either DMSO or nocodazole (100ng/ml) for five hours, after which they
were lysed in 1× lysis buffer along with protease inhibitors (PMSF, Aprotinin and LAP) and10
mM NEM. The 1× lysis buffer was obtained by diluting 2× SSB (5% SDS, 150 mM Tris-HCl pH
6.7, 20% glycerol) with 1× RIPA buffer (20mM HEPES pH 8.0, 300 mM NaCl, 2 mM EDTA,
0.5% sodium deoxycholate, 1% Triton X-100, and 6% glycerol) in 1:4 ratio. The cell lysates were
then sonicated and centrifuged at 14,000 rpm at 4oC for 10 min. The supernatant was bound to
anti-FLAG M2 beads (Sigma) for five hours at 4oC. The beads were then washed for five times in
wash buffer (20 mM HEPES pH 8.0, 750 mM NaCl, 2 mM EDTA, 0.5% sodium deoxycholate,
1% Triton X-100, 6% glycerol, 0.1% SDS, and 10 mM NEM). The immunopurified proteins were
eluted in 2x SDS Sample Buffer and run on an SDS-PAGE followed by immunoblot analysis using
anti-FLAG and anti-SUMO-2/3 antibodies.
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3.4 RESULTS
3.4.1 Nuf2 is important for recruiting CENP-E to kinetochores and mitotic
progression
Nuf2 is an outer kinetochore protein required for stable microtubule-kinetochore
attachments and chromosome congression to the metaphase plates (McCleland et al., 2003). Nuf2
is localized to the outer kinetochores throughout mitosis (DeLuca et al., 2002). There are two
contradicting studies about if Nuf2 is required for CENP-E localization to kinetochores during
mitosis. One study shows that Nuf2 is critical for the kinetochore localization of CENP-E in HeLa
cells (Liu et al., 2007), whereas the other one, which was also performed in HeLa cells using the
same siRNA oligos to knockdown Nuf2, showed that Nuf2 is dispensable for CENP-E targeting
to kinetochores (DeLuca et al., 2002). Therefore, I first investigated the role of Nuf2 in localizing
CENP-E to the kinetochores. HeLa cells were transfected with either scrambled RNAi oligos or
with one of the two RNAi oligos, siRNA 1 (DeLuca et al., 2002; Liu et al., 2007) and siRNA 2,
against Nuf2. After 72 hours, the cells were lysed and the efficiency of knockdown was tested by
Western blot analysis using antibodies against Nuf2 (Figure 3.1A). A significant knockdown in
the levels of Nuf2 were observed when either of the oligos specific to Nuf2 was used compared to
the scrambled RNAi oligos. Next, in order to test if Nuf2 is required for CENP-E localization to
the kinetochores, HeLa cells were transfected with either scrambled siRNA oligos or siRNA oligos
specific to Nuf2. 72 hours after transfection, cells were fixed and stained with anti-Nuf2 and antiCENP-E antibodies. It was found that control cells had obvious CENP-E staining on the mitotic
chromosomes, whereas most of the cells treated with Nuf2 siRNA oligos had no detectable
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Figure 3.1. Nuf2 is required for CENP-E localization to kinetochores. (A to E) HeLa cells were transfected with
either scrambled oligos or with two siRNA oligos (1 and 2) against Nuf2. After 72 hours, (A) cells were lysed and a
WB analysis was performed against anti-Nuf2 and anti-tubulin antibodies, (B) cells were fixed and
immunofluorescence was performed with anti-CREST and anti-CENP-E antibodies, (C) % of mitotic cells (Pro:
Prophase, Met: Metaphase, A&T: Anaphase and Telophase) with no obvious CENP-E staining was counted, (D)
mitotic index for each transfection was calculated, (E) % of mitotic cells in each phase of mitosis was calculated.

CENP-E staining on the chromosomes (Figure 3.1B). This result firmly establishes that Nuf2 is
required for kinetochore localization of CENP-E. We found that more than 75% of mitotic cells
transfected with either of the oligos against Nuf2 had no CENP-E on the kinetochores (Figure
3.1C) whereas, in cells transfected with scrambled RNAi, only about 5% of mitotic cells had lost
CENP-E staining from the kinetochores. Consistent with previous studies (DeLuca et al., 2002;
Hori et al., 2003), depleting Nuf2 resulted in a mitotic index of 20-27% depending on the oligos

79

(Figure 3.1D). Moreover, about 95% of the mitotic cells were arrested in prometaphase when cells
were transfected with either of the siRNA oligos against Nuf2 with only less than 5% of cells in
the other three phases of mitosis. Whereas in the control cells there was almost an equal
distribution of cells in different phases of mitosis (Figure 3.1E).

3.4.2 SUMO modification at kinetochores is required for chromosome
segregation by recruiting CENP-E to kinetochores
Inhibition of SUMOylation by over expression of Myc-SENP2 causes a prometaphase
arrest and mislocalization of CENP-E from the kinetochores (Zhang et al., 2008). In addition to
being a SUMO-2/3 target, CENP-E has a bona fide SUMO Interacting Motif (2307-2319aa) in its
C-terminal domain which is required for its localization to the kinetochores. Two of the CENP-E
interacting outer kinetochore proteins, BubR1 and Nuf2, are specifically modified by SUMO-2/3
in vivo (Zhang et al., 2008). Based on these observations, we hypothesize that SUMO modification
of one or more kinetochore proteins including Nuf2 recruits CENP-E to the kinetochores via its
SIM facilitating the chromosomes to align on the metaphase plates. A potential way to test this
would be to enhance the SUMOylation of Nuf2 by increasing the local concentration of Ubc9 in
the centromere region (Jakobs et al., 2007). In order to accomplish this, we made a fusion
construct, FLAG-Nuf2-Ubc9, where Ubc9 was fused to the C-terminus of Nuf2. We also fused
the catalytic mutant of Ubc9 (Azuma et al., 2003; Banerjee et al., 1995) to the C-terminus of Nuf2,
FLAG-Nuf2-Ubc9 (C93A) in order to understand if SUMOylation caused by Ubc9 contributes to
cell cycle progression through mitosis. The construct FLAG-Nuf2 was used as a control. A
schematic of these constructs is shown in Figure 3.2A. These constructs were transfected in to
293T cells and a western blot analysis of the cell lysates indicated that the different FLAG-tagged
Nuf2 fusion proteins were expressed with the expected size (Figure 3.2B). In order to test if fusing
Ubc9 to Nuf2 enhances SUMO-2/3 modification of Nuf2, 293T cells were transfected with either
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FLAG-Nuf2 or FLAG-Nuf2-Ubc9 (WT). 48 hours after transfection, immunoprecipitation using
anti-FLAG beads were performed. The immunopurified proteins were run on an SDS-PAGE and
a WB analysis using anti-SUMO-2/3 antibodies indicated the SUMO-modified forms of Nuf2.
Although there was no difference between higher molecular weight conjugates of Nuf2 when
transfected with either of the two constructs, there were three specific bands when transfected with
FLAG-Nuf2-Ubc9 (WT) but not in FLAG-Nuf2, which are indicated with asterisk.

Figure 3.2. SUMO modification at kinetochores is required for chromosome segregation by recruiting CENPE to kinetochores. (A) Diagram showing the different FLAG-Nuf2 constructs. (B) 293T cells expressing each of the
FLAG-Nuf2 constructs were lysed and blotted with anti-FLAG antibodies. (C) 293T cells were transfected with either
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FLAG-Nuf2 or FLAG-Nuf2-Ubc9. 48 hours after transfection, IP using anti-FLAG beads was performed followed by
WB using anti-FLAG and anti-SUMO-2/3 antibodies. (D-G) HeLa cells were co-transfected with Myc-SENP2 along
with one of the FLAG-Nuf2 constructs for 48 hours, after which the cells were fixed and stained with anti-FLAG and
anti-Myc antibodies (D) or stained with anti-Myc and anti-CENP-E antibodies (F). Percentages (%) of cells in different
stages of mitosis in each of these transfections were counted and quantified (E and G).

To test if enhancing SUMO modification of Nuf2 can rescue the phenotypes caused by
Myc-SENP2 overexpression, we transfected HeLa cells with Myc-SENP2 along with a construct
expressing FLAG-Nuf2 (a negative control), FLAG-Nuf2-Ubc9 (WT), or FLAG-Nuf2-Ubc9
(C93A) (a negative control). 48 hours after transfection, the cells were fixed and stained with both
anti-FLAG and anti-Myc antibodies. Immunofluorescence microscopy analysis showed the
percentage of transfected cells in each phase of mitosis. While only about 2 or 4% of cells with
over-expression of Myc-SENP2 had their chromosomes aligned on the metaphase plates when
transfected with either FLAG-Nuf2 or FLAG-Nuf2-Ubc9 (C93A), cells transfected with FLAGNuf2-Ubc9 (WT) had about 9% of Myc-SENP2 transfected cells in any of the three phases of
mitosis including metaphase and anaphase/telophase (Figure 3.2D and E). Next, in order to check
whether the chromosome congression to metaphase plates were due to CENP-E targeting to the
kinetochores in these cells, we performed similar transfections as mentioned above (Myc-SENP2
along with either FLAG-Nuf2, FLAG-Nuf2-Ubc9 (WT) or FLAG-Nuf2-Ubc9 (C93A)) and
stained the cells with anti-Myc and anti-CENP-E antibodies. Consistent with our model that the
SUMO modification of one or more kinetochore proteins recruits CENP-E to kinetochores, we
found that there were about 2.5 to 3 times increase in the number of mitotic cells that had rescued
CENP-E mislocalization caused by inhibition of SUMOylation in cells transfected with FLAGNuf2-Ubc9 (WT) compared to cells transfected with FLAG-Nuf2-Ubc9 (C93A) or FLAG-Nuf2
(Figure 3.2F and G). These results therefore indicate that fusing Ubc9 (WT) to Nuf2 leads to
CENP-E targeting to kinetochores in cells overexpressing SENP2.
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3.4.3 Nuf2 is modified by polymeric SUMO-2/3 chains both in vivo and in vitro
Previous studies have indicated that Nuf2 is specifically modified by SUMO-2/3 in vivo
(Zhang et al., 2008). However, an in vitro SUMO modification assay using recombinant Nuf2, E1
activating enzyme, Ubc9 and along with either SUMO-1 or SUMO-2 indicated that Nuf2 can be
robustly modified by either SUMO with equal efficiency (Figure 3.3B). Since the function of Nuf2
is well established during mitosis, we wanted to test if the SUMO-2 modification of Nuf2 is
enhanced when cells are enriched in mitotic phase compared to asynchronous cells. In order to
examine that, 293T cells were transfected with FLAG-Nuf2 for 48 hours after which the cells were
treated with either DMSO (control) or nocodazole (to arrest cells in prometaphase) for five hours.
Immunoprecipitation using anti-FLAG beads followed by WB using anti-FLAG and anti-SUMO2/3 antibodies was performed. The levels of SUMO-2/3 modification on Nuf2 were slightly higher
in cells treated with nocodazole, indicating that SUMO-2/3 modification of Nuf2 increases to some
extent during mitosis (Figure 3.3A). The higher molecular weight smear of SUMO-2/3
modification on Nuf2 (Figure 3.3A) could either indicate polymeric SUMO-2/3 chain modification
of Nuf2 on one/more lysine residues or monomeric SUMO-2/3 modification of Nuf2 on several
lysine residues. In order to distinguish these two possibilities, we turned to the in vitro SUMO
modification assay using recombinant proteins with either WT or chain deficient mutant of
SUMO-1. Purified Nuf2 was incubated with recombinant SUMO E1 and Ubc9 in the presence of
SUMO-1 WT or K-less mutant for the indicated times (Figure 3.3D). Although we could observe
a few modified bands of Nuf2 using the K-less mutant, the higher molecular weight bands of
SUMO-1 modified Nuf2 was obvious only when SUMO-1 WT was used, suggesting that Nuf2 is
preferentially modified by polymeric SUMO-1 chains. In order to confirm that the efficiency of
the first modification on a substrate is similar between WT and K-less mutant of SUMO-1, we
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Figure 3.3. Nuf2 is modified by polymeric SUMO-2/3 chains. (A) 293T cells were transfected with FLAG-Nuf2
for 48 hours after which cells were treated with DMSO as control or with nocodazole for five hours. IP with antiFLAG beads followed by WB with anti-FLAG and anti-SUMO-2/3 antibodies was performed. (B) In vitro
SUMOylation assay for two hours with Nuf2, SUMO-1 or SUMO-2, recombinant E1 and E2, followed by WB
analysis using the specified antibodies. (C) Similar in vitro SUMOylation as in (B) but with purified
RanGAP1(NΔ419) as substrate using either SUMO-1 WT or K-less mutant (D) Similar in vitro SUMOylation assay
as in (B) with purified Nuf2 along with either SUMO-1 WT or K-less mutant.

performed a control experiment using RanGAP1 as the substrate (Figure 3.3C). A similar in vitro
SUMOylation assay was performed for the indicated times which showed that the first
modification on RanGAP1 was similar irrespective of whether WT or K-less mutant was used.

3.4.4 Polymeric SUMO-2 chain fused to Nuf2 is critical for CENP-E
localization to kinetochores and chromosome alignment to metaphase plates
As shown in Figure 3.2, we found that FLAG-Nuf2-Ubc9 (WT) can rescue the mitotic
defects caused by SENP2 overexpression. However, Ubc9 fused to Nuf2 can potentially enhance
both SUMO-1 and SUMO-2/3 modification of kinetochore proteins including Nuf2. In addition,
our results strongly suggested that Nuf2 is primarily modified by polymeric SUMO chains in vitro
(Figure 3.3). We therefore asked if polymeric SUMO-1 or SUMO-2/3 modification caused by
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FLAG-Nuf2-Ubc9 rescues the phenotype caused by SENP2 overexpression. To address this
question, three constructs encoding FLAG-Nuf2, FLAG-Nuf2-3xSUMO-1 and FLAG-Nuf23xSUMO-2 were generated, where three SUMO-1 or SUMO-2 moieties in tandem were cloned to
the C-terminus of Nuf2. These SUMO-1 and SUMO-2 chains are non-cleavable as the terminal
GG motifs of SUMO-1 and SUMO-2 have been mutated to AA (Figure 3.4A). The protein encoded
by these constructs show the expected size when transfected into 293T cells, lysed and blotted
with anti-FLAG antibodies (Figure 3.4B). Our WB results confirmed that the fusion proteins
expressed were not cleaved by endogenous SENP2 as expected. In order to understand if polymeric
SUMO-1 or SUMO-2 modification of kinetochore proteins is essential for cell cycle progression
through mitosis, we transfected HeLa cells with Myc-SENP2 (to inhibit SUMOylation) along with
the plasmid encoding FLAG-Nuf2, FLAG-Nuf2-3xSUMO-1 or FLAG-Nuf2-3xSUMO-2. Using
indirect immunofluorescence microscopy, we found that the mitotic cells expressing Myc-SENP2
and FLAG-Nuf2-3xSUMO-2 had about four fold higher percentage of metaphase cells compared
to those expressing Myc-SENP2 and FLAG-Nuf2 or FLAG-Nuf2-3xSUMO-1 (Figures 3.4C and
D). Next, we asked if the rescue of chromosome congression defect by FLAG-Nuf2-3xSUMO-2
in Myc-SENP2 overexpressing cells is due to CENP-E targeting to the kinetochores. To answer
this question, we transfected cells with the plasmid encoding Myc-SENP2 along with either the
construct expressing FLAG-Nuf2, FLAG-Nuf2-3xSUMO-1 or FLAG-Nuf2-3xSUMO-2, fixed the
cells and stained with anti-FLAG and anti-CENP-E antibodies. Interestingly, we found that about
13% cells have CENP-E localization in the kinetochores when cells were transfected with FLAGNuf2-3xSUMO-2, while only about 5% cells had CENP-E localized to the kinetochores when cells
were transfected with FLAG-Nuf2 or FLAG-Nuf2-3xSUMO-1(Figures 3.4E and F). These results
clearly indicate that polymeric SUMO-2 chains at the kinetochores play an important role in
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localizing CENP-E to the kinetochores, thereby allowing cells to align their chromosomes on
metaphase plates. This is consistent with the result that Nuf2 is specifically polymeric SUMO-2/3
modified in vivo and that CENP-E binds to SUMO-2 polymeric chains and not SUMO-1 chains in
vitro (Zhang et al., 2008).

Figure 3.4. Polymeric SUMO-2 chain modification of Nuf2 is critical for CENP-E localization to kinetochores
and therefore chromosome alignment to metaphase plates. (A) Diagram showing the different Nuf2 constructs.
(B) 293T cells were transfected with the different Nuf2 fusion constructs. 48hours after transfection, cells were lysed
and blotted with anti-FLAG antibodies. (C-F) HeLa cells were cotransfected with Myc-SENP2 along with one of the
FLAG-Nuf2 constructs. After 48 hours, cells were fixed and stained with anti-FLAG and anti-Myc antibodies (C)
with anti-CENP-E and anti-Myc antibodies (E). The transfected cells in each stage of mitosis was counted and
quantified in D (results from C) and F (results from E).
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3.4.5 A minimum of trimeric SUMO-2 chain fused to Nuf2 is required for
targeting CENP-E to kinetochores in cells overexpressing SENP2
Recent studies have shown that the yeast strains incapable of forming SUMO chains have
defects in chromosome segregation during mitosis (Srikumar et al., 2013). These yeast strains were
expressing smt3allR proteins, in which all the lysine residues were mutated to arginine. Although
several studies have indicated that SUMOylation plays an important role in mitotic progression
(Ban et al., 2011; Fernandez-Miranda et al., 2010; Mukhopadhyay et al., 2010; Yang et al., 2011),
it is still not clear about the exact role of monomeric or polymeric SUMO modification during
mitotic progression especially in vertebrate cells. To get a better understanding on the role of
polymeric SUMO-2/3 chain in chromosome congression and CENP-E localization to the
kinetochores, we generated the constructs expressing a monomeric (FLAG-Nuf2-SUMO-2),
dimeric (FLAG-Nuf2-2xSUMO-2) or trimeric (FLAG-Nuf2-3xSUMO-2) SUMO-2 fused to the
C-terminus of Nuf2 (Figure 3.5A). Our immunoblot analysis showed that the proteins expressed
by these constructs are of the expected size (Figure 3.5B). HeLa cells were transfected with MycSENP2 along with FLAG-Nuf2 (as a negative control), FLAG-Nuf2-SUMO-2, FLAG-Nuf22xSUMO-2 or FLAG-Nuf2-3xSUMO-2 and stained with anti-FLAG and anti-Myc antibodies.
Using indirect immunofluorescence microscopy, the percentage of transfected mitotic cells in each
case was analyzed. Only 1.5% mitotic cells transfected with FLAG-Nuf2, FLAG-Nuf2-SUMO-2,
or FLAG-Nuf2-2xSUMO-2 had their chromosomes aligned on the metaphase plates compared to
7.5% mitotic cells expressing FLAG-Nuf2-3xSUMO-2 at metaphase (Figure 3.5C and D).
Consistent with our previous results of CENP-E localization (Figure 3.4E and F), FLAG-Nuf23xSUMO-2 overexpression significantly increased the percentage of SENP2-overexpressing cells
with CENP-E localization at the mitotic chromosomes (11.5%) in comparison to FLAG-Nuf2
(5%), FLAG-Nuf2-SUMO-2 (4%) and FLAG-Nuf2-2xSUMO-2 (5%) (Figures 3.5E and F). This
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result indicates that a minimum of three SUMO-2 fused to the C-terminus of Nuf2 is required to
rescue the defects in CENP-E localization to kinetochore and chromosome congression in cells
overexpressing SENP2.

Figure 3.5. A minimum of trimeric SUMO-2 chain fused to Nuf2 is required for targeting CENP-E to
kinetochores in cells overexpressing SENP2. (A) Diagram showing the Nuf2 constructs with different SUMO-2
chain lengths. (B) The FLAG-Nuf2 constructs with varying chain lengths of SUMO-2 fused to its C-terminal was
transfected into 293T cells. The cell lysates were collected 48 hours post transfection and were run on an SDS-PAGE
gel and a WB using anti-FLAG antibodies was performed. (C and E) HeLa cells were cotransfected with Myc-SENP2
along with one of the FLAG-Nuf2 fusion constructs shown in A. 48 hours after transfection, cells were fixed and
stained with anti-FLAG and anti-Myc antibodies in (C) and anti-CENP-E and anti-Myc antibodies in (E). (D and F)
Transfected cells were counted for chromosome alignment in (D) and CENP-E localization in (F).
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3.4.6 Nuf2-3xSUMO-2 can localize more CENP-E compared to Nuf2 in cells
depleted with Ubc9
It has been shown previously that inhibition of SUMOylation by either SENP2
overexpression or RNAi-depletion of Ubc9 causes a loss of CENP-E from kinetochores (Zhang et
al., 2008). In Figures 3.4 and 3.5, I have shown that FLAG-Nuf2-3xSUMO-2 can recruit more
CENP-E compared to FLAG-Nuf2 in cells with overexpression of SENP2. In order to confirm the
above finding using another approach to inhibit SUMOylation (depletion of Ubc9), HeLa cells
were first transfected with either siRNA oligos against Ubc9 or with control siRNA oligos for 72
hours, lysed, and analyzed by immunoblotting with anti-tubulin and anti-Ubc9 antibodies. The
results indicate that the RNAi-knockdown of Ubc9 was very efficient (Figure 3.6A). Further, to
test the above hypothesis, Ubc9 siRNA treated cells were transfected with either FLAG-Nuf2 or
FLAG-Nuf2-3xSUMO-2 for 48 hours followed by fixing the cells with 3.5% paraformaldehyde.
The fixed cells were then stained with anti-FLAG and anti-CENP-E antibodies.

Figure 3.6. Nuf2-3xSUMO-2 can localize more CENP-E compared to Nuf2 in cells depleted with Ubc9. (A)
HeLa cells were transfected with control or Ubc9 specific siRNA oligos for 72 hours and analyzed by WB with antitubulin (loading control) and anti-Ubc9 antibodies. (B) HeLa cells were transfected with Ubc9 siRNA oligos. 24 hours
after transfection, cells were transfected with either FLAG-Nuf2 or FLAG-Nuf2-3xSUMO-2. After 48 hours, cells
were fixed and stained with anti-CENP-E antibodies. Using immunofluorescence microscopy, transfected cells with
CENP-E staining were counted and quantified.
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About 37% of cells expressing FLAG-Nuf2-3xSUMO-2 had CENP-E staining on mitotic
chromosomes compared to only about 10% of FLAG-Nuf2-expressing cells with CENP-E
staining. The percentage of cells with CENP-E staining in both FLAG-Nuf2 and FLAG-Nuf23xSUMO-2 cells (Figure 3.6) was calculated by subtracting the percentage of non-transfected cells
from transfected cells. This indicates that polymeric SUMO-2 chains at the kinetochore recruits
CENP-E in cells with global inhibition of SUMOylation using two independent approaches overexpression of SENP2 (Figure 3.4) and depletion of Ubc9 (Figure 3.6).

3.4.7 Nuf2-3xSUMO-2 has a higher binding to CENP-E than Nuf2
Since FLAG-Nuf2-3xSUMO-2 can recruit CENP-E to centromeres better than FLAGNuf2 in cells with SENP2 overexpression or Ubc9 depletion, we hypothesized that Nuf23xSUMO-2 has better affinity to CENP-E compared to Nuf2. To test this idea, we performed an
in vitro binding assay, where purified GST, GST-Nuf2 or GST-Nuf2-3xSUMO-2 was
immobilized on Glutathione beads. The tail domain of FLAG tagged CENP-E was transiently
expressed in 293T cells, and the cell lysates were passed through the glutathione beads containing
the above mentioned GST or GST-tagged fusion proteins. The tail domain of CENP-E contains
the SIM, kinetochore targeting domain and is about 750 aa in length. After binding for five hours
at 4oC, the beads were washed and the proteins were eluted in 2x SSB followed by immunoblot
analysis using anti-FLAG antibodies. Levels of FLAG-tagged CENP-E were quantified using
ImageJ and normalized with GST levels (Figures 3.7A and 3.7B top panel). We found that the
binding affinity between GST-Nuf2-3xSUMO-2 and FLAG-CENP-E is about three fold higher
when compared to the binding affinity between GST-Nuf2 and FLAG-CENP-E (Figure 3.7C left
panel).
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Figure 3.7. Nuf2-3xSUMO-2 has higher binding affinity to CENP-E than Nuf2. (A and B) GST, GST-Nuf2 or
GST-Nuf2-3xSUMO-2 were purified using Glutathione beads. 293T cell lysates overexpressing the tail domain of
either WT CENP-E or SIM deficient mutant of CENP-E were passed over Glutathione beads containing any of the
GST proteins. The beads were then washed and eluted using SDS sample buffer. The eluted proteins were run on an
SDS-PAGE and blotted with either anti-GST (A), or anti-FLAG (B) antibodies. The quantified results are shown in
C.

Given that Nuf2 can interact with CENP-E (Liu et al., 2007), our results suggested that
CENP-E binds better to Nuf2-3xSUMO-2 than Nuf2 through the interaction between the SIM
motifs of CENP-E and the SUMO-2 moieties of Nuf2-3xSUMO-2. If this were true, the binding
affinity between FLAG-CENP-E SIM mutant and GST-Nuf2-3xSUMO-2 should be comparable
to that between FLAG-CENP-E and GST-Nuf2. To test this, we performed a similar binding assay
with FLAG-CENP-E SIM mutant. We found that FLAG-CENP-E SIM mutant bound to both
GST-Nuf2 and GST-Nuf2-3xSUMO-2 with the similar binding affinity (Figures 3.7B bottom
panel and 3.7C right panel). These results indicate that the trimeric SUMO-2 chains of GST-Nuf23xSUMO-2 interact with the SIM(s) of CENP-E and enhances the interaction between CENP-E
and Nuf2-3xSUMO-2.
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3.4.8 Nuf2 is SUMO-2 modified at several lysine residues
From previous studies and from Figure 3.3, we know that Nuf2 is modified by SUMO-2
both in vitro and in vivo (Zhang et al., 2008). We next set out to identify the major SUMOylation
sites on Nuf2. We made use of bioinformatics tools, GPS-SUMO 1.0 and SUMOplot, to identify
the top six putative SUMOylation sites on Nuf2 (Figure 3.8A).

Figure 3.8. Nuf2 is SUMO-2 modified at several lysine residues. (A) The diagram shows the top six putative SUMO
modification consensus motifs of Nuf2 with the lysine residues in red. (B) In vitro SUMO-2 modification assay with
either purified Nuf2 (WT) or Nuf2 with all the six lysine residues mutated to arginine (6x K/R) simultaneously was
performed along with the SUMO conjugation machinery for the indicated times followed by WB analysis using antiNuf2 antibodies.

After mutating the six lysine residues to arginine simultaneously (6K/R), an in vitro
SUMO-2 modification assay was performed, using Nuf2 as the substrate along with recombinant
E1, E2 and ATP regeneration system (Figure 3.8B). The SUMO-2 modified chain of Nuf2 were
comparable irrespective of whether WT or 6K/R mutant form of Nuf2 was used. This suggests that
other lysine residues on Nuf2 could be modified by SUMO-2.

3.5 DISCUSSION
Previously, polymeric SUMO-2/3 modification of substrates like PML and CENP-I have
been linked to degradation via the proteasome (Lallemand-Breitenbach et al., 2008;
Mukhopadhyay et al., 2010). Polymeric SUMO-2/3 chain modification of PML recruit RNF4, a
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SUMO targeted E3 ubiquitin ligase containing four SIMs in tandem. Studies in budding yeast have
shown that ZIP1 interacts with Smt3 chains but not its monomers (Cheng et al., 2006a). Despite
previous studies indicating the importance of polymeric SUMO chains, our study provided the
first direct evidence that polymeric SUMO-2/3 chains plays a critical role during mitosis by
targeting CENP-E to kinetochores and subsequent chromosome alignment to metaphase plates. It
is very interesting to reveal that the trimeric SUMO-2/3 chain modification can act as a specific
signal distinct from the trimeric SUMO-1 modification and the monomeric and dimeric SUMO2/3 modifications, in this case, for targeting the polymeric SUMO-2/3 chain-binding protein,
CENP-E, to kinetochores.
Our results strongly suggest that polymeric SUMO-2/3 chains at the kinetochore region are
required for CENP-E recruitment, chromosome alignment and segregation. There is a significant
rescue in both chromosome alignment and CENP-E localization when cells are transfected with
FLAG-Nuf2-3xSUMO-2 or FLAG-Nuf2-Ubc9 compared to FLAG-Nuf2 in cells with
overexpression of SENP2. If we could assume that mitotic cells are equally distributed among the
three stages: prophase/prometaphase, metaphase and anaphase/telophase, we would expect about
60% of mitotic cells in metaphase and anaphase/telophase together if there was a complete rescue
of chromosome segregation in cells with overexpression of SENP2 along with FLAG-Nuf23xSUMO-2 or FLAG-Nuf2-Ubc9. Nevertheless, as expected, we were not able to achieve
complete rescue for both chromosome segregation and CENP-E localization when SUMOylation
is inhibited by SENP2 overexpression using either FLAG-Nuf2-3xSUMO-2 or FLAG-Nuf2-Ubc9
constructs and there could be several possibilities for partial rescue. First, trimeric SUMO-2 chain
is probably insufficient for effective CENP-E recruitment and thereby chromosome alignment. A
longer length of SUMO-2 chain fused to Nuf2 would probably achieve a higher percentage of
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rescue of these mitotic defects than Nuf2-3xSUMO-2. Second, polymeric SUMO-2/3 modification
of the other CENP-E interacting kinetochore proteins other than Nuf2 (for example, BubR1 and
CENP-F), may also contribute to CENP-E recruitment and chromosome segregation. Transfecting
cells with a construct consisting of SUMO-2 chains fused to either BubR1 or CENP-F might
improve the percentage of CENP-E rescue. Third, though the FLAG-Nuf2-3xSUMO-2 fusion
construct was intended to mimic endogenous Nuf2 SUMOylation, it might not truly replicate
endogenous Nuf2 SUMO-2/3 modification. This is because the orientation of the linear SUMO-2
chains within the Nuf2-3xSUMO-2 fusion protein is different from the natural polymeric SUMO2/3 modification of Nuf2.
Compared to FLAG-Nuf2-3xSUMO-2, FLAG-Nuf2-Ubc9 is able to rescue the defects in
chromosome segregation and CENP-E localization to kinetochores more efficiently in cells with
inhibition of SUMOylation by SENP2 overexpression. One explanation is that SUMO
modification on Nuf2 brought by FLAG-Nuf2-Ubc9 is cleavable and this deSUMOylation at the
centromeres is required for CENP-E to exit the chromosomes and localize to the spindle midzone
during anaphase/telophase. However, the trimeric SUMO-2 chain in FLAG-Nuf2-3xSUMO-2 is
non-cleavable and therefore might probably prevent CENP-E from exiting the chromosomes and
inhibiting the cells from passing through metaphase.
Using the GPS SUMO1.0 and JASSA software, we found that there are at least five other
putative SUMO Interacting Motifs in the tail domain of CENP-E. They are from amino acid
residues 2034-2037, 2209-2212, 2439-2442, 2464-2467, 2495-2498. Since we show that a
minimum of trimeric SUMO-2 chain fused to Nuf2 is essential to rescue CENP-E mislocalization
caused by SENP2 overexpression, it is possible that one or more of these putative SIM(s) binds to
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polymeric SUMO modified Nuf2 and hence plays an important role in CENP-E localization to
kinetochores.
CENP-E first appears on the centromeres during prometaphase (Brown et al., 1994; Yen
et al., 1991; Yen et al., 1992). Nuf2 is found in the cytosol during interphase and is targeted to the
centromeres throughout mitosis (Hori et al., 2003). Since we have shown that SUMOylation of
kinetochore proteins including Nuf2 is critical for CENP-E localization to the kinetochores it
would be interesting to examine if SUMOylation of Nuf2 occurs prior to CENP-E targeting to
kinetochores.
In this study, we focused on investigating if SUMOylation of Nuf2, one of the known
CENP-E interacting proteins, plays a critical role in targeting CENP-E to kinetochores. Further, it
would be interesting to understand how its SUMO-2/3 modification is regulated. The E3 ligase
identified can be used as a tool to regulate SUMO-2/3 modification of Nuf2, thereby gaining more
insight into the mechanism of CENP-E localization to the kinetochores.
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CHAPTER 4 FUTURE DIRECTIONS
4.1 Which PIAS protein stimulates the SUMO-2 modification of Nuf2?
SUMOylation of quite a few mitotic targets are regulated by PIAS family E3 ligases
(Azuma et al., 2005; Ban et al., 2011; Fernandez-Miranda et al., 2010; Sridharan et al., 2015).
PIAS proteins contain an N-terminal SAP domain that is involved in DNA binding, PINIT domain
required for their sub-cellular localization, SP-RING domain that contains the SUMO E3 ligase
activity, SIM for non-covalent SUMO interactions, and S/T domain (the serine threonine rich
domain) (Rytinki et al., 2009) . In mammalian cells, PIAS3-mediated SUMO-2/3 modification of
Aurora-B enhances its autophosphorylation that is required for its activation (Ban et al., 2011). In
Xenopus, one of the major SUMO-2/3 substrates associated with mitotic centromeres is Topo IIα
(Azuma et al., 2003). SUMO-2/3 modification of Topo IIα is spatially and temporally regulated
by PIASy (Azuma et al., 2005). SUMOylation of Topo IIα by PIASy is required for the recruitment
of Topo IIα to the centromere (Diaz-Martinez et al., 2006). Polo-like kinase 1-interacting
checkpoint helicase (PICH) is a protein essential for mitotic progression, especially during
chromosome segregation (Kurasawa and Yu-Lee, 2010). SUMOylation of PICH is regulated by
PIASy and decreases its binding to mitotic chromosomes in vitro (Sridharan et al., 2015).
Based on these data, we hypothesized that one of the PIAS proteins is critical for Nuf2
SUMOylation. Identifying the E3 ligase could be another potential way to test if Nuf2
SUMOylation is important for CENP-E targeting to the kinetochore. We performed a preliminary
in vitro binding assay to test if Nuf2 binds to any of the proteins from the PIAS family. GST-Nuf2
was purified from E.coli using Glutathione beads. 293T whole cell lysates over expressing each of
the FLAG-PIAS proteins was passed through Glutathione beads containing GST-Nuf2. The beads
were washed and the bound proteins were eluted. The eluted proteins were run on an SDS-PAGE
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and a Western blot analysis using anti-FLAG antibodies was performed (Figure 4.1A). The results
indicated that both PIASxα and PIASy specifically interact with Nuf2. Of the different PIAS
proteins, PIAS3 and PIASy are known to be localized to the kinetochores during mitosis
(Agostinho et al., 2008; Ban et al., 2011) . We then performed an in vivo co-immunoprecipitation
assay between Nuf2 and two of the PIAS proteins, PIAS3 and PIASy. PIAS3 was used as a
negative control. 293T cells were co-transfected with FLAG-Nuf2 along with either GFP-PIAS3
or GFP-PIASy. 24 hours post transfection, anti-FLAG beads were used to pull down Nuf2 under
non-denaturing conditions. The proteins bound to the beads were eluted and run on an SDS-PAGE
gel followed by WB analysis using anti-FLAG and anti-GFP antibodies. Nuf2 interacted more
efficiently with PIASy compared to PIAS3 (Figure 4.1B). We then performed an in vitro
SUMOylation assay to test if PIASy stimulates Nuf2 SUMOylation (Figure 4.1C). Nuf2 along
with E1, E2, with the ATP regenerating system was present in all lanes. The first lane without
SUMO-2 was used as a negative control. The second lane with SUMO-2 showed higher molecular
weight SUMO conjugates of Nuf2. The third lane was another negative control which had SUMO2 and the buffer in which purified PIASy was dissolved. The fourth lane had SUMO-2 along with
purified recombinant PIASy. There was no increase in the SUMO-modified forms of Nuf2 with
addition of PIASy by comparing lanes 3 and 4 (Figure 4.1C). We then performed an in vivo
experiment to test if PIASy stimulates Nuf2 SUMOylation. 293T cells were transfected with
FLAG-Nuf2 along with one of the following constructs - the empty vector, GFP-PIAS3, and GFPPIASy, respectively. FLAG-Nuf2 was pulled down under denaturing conditions using anti-FLAG
beads and the SUMOylation of Nuf2 under each of these conditions was analyzed by
immunoblotting with antibodies against SUMO-1, SUMO-2/3, GFP, FLAG and tubulin. We found
that the SUMOylation of Nuf2 was the highest when empty vector was transfected. However,
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SUMOylation of Nuf2 was more abundant when GFP-PIASy was used compared to GFP-PIAS3
(Figure 4.1D). From Figures 4.1C and D, we cannot conclude if PIASy stimulates Nuf2
SUMOylation.

Figure 4.1. What is the E3 ligase that stimulates Nuf2 SUMOylation? (A) 293T cells over expressing one of the
five FLAG-PIAS proteins were passed over Glutathione beads containing GST-Nuf2 proteins. The bound proteins
were eluted with 2xSSB and the eluted proteins were run on an SDS-PAGE following which WB analysis against αFLAG antibodies was performed. (B) 293T cells were transfected with FLAG-Nuf2 along with either GFP-PIAS3 or
GFP-PIASy. Under non-denaturing conditions, the cell lysates were purified using anti-FLAG beads. The bound
proteins were eluted and a WB analysis against anti-FLAG and anti-GFP was performed. (C) An in vitro SUMOylation
assay was performed with purified Nuf2, E1 activating enzyme, E2 conjugating enzyme in all the lanes, along with
SUMO-2, PIASy as indicated. (D) 293T cells were transfected with FLAG-Nuf2 along with one of the following as
indicated-empty vector, GFP-PIAS3 or GFP-PIASy. Under denaturing conditions, FLAG-Nuf2 was purified using
anti-FLAG beads and a WB analysis was performed against anti-FLAG antibodies and anti-SUMO-2/3 antibodies to
detect SUMO-2/3 modified forms of Nuf2.
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Further experiments should be performed in order to identify the E3 ligase for Nuf2. To
make sure the purified PIASy is catalytically active, the in vitro SUMOylation reaction in Figure
4.1C can be repeated using a positive control (Topo IIα whose SUMOylation is known to be
stimulated by PIASy (Azuma et al., 2005)). Another possibility is that PIASxα stimulates SUMO2/3 modification of Nuf2. To test this, in vitro SUMOylation reaction similar to the one in Figure
4.1C can be performed using purified PIASxα instead of PIASy.

4.2 Do multiple SIM motifs at CENP-E tail domain mediate the interaction of
CENP-E with polymeric SUMO-2/3 modified Nuf2?
The known polymeric SUMO chain interacting proteins, including RNF4, Arcadia, and
ZMYM2, have at least three SIMs that contribute to their binding to SUMO-2 chains (AguilarMartinez et al., 2015; Erker et al., 2013; Sun and Hunter, 2012; Tatham et al., 2008). However, so
far only one SIM (SIM3 in Figure 4.2) has been identified in CENP-E that is important for binding
to polymeric SUMO-2 chains and for its kinetochore localization (Zhang et al., 2008). Moreover,
in vitro CENP-E binds to polymeric SUMO-2 chains rather than monomeric SUMO similar to
RNF4 (Xu et al., 2014). Also, from Chapter 3, we know that Nuf2-3xSUMO-2 targets CENP-E to
the kinetochores better than Nuf2-SUMO-2 or Nuf2-2xSUMO-2 in cells with overexpression of
SENP2. Based on these observations, we hypothesized that there are multiple SIMs in CENP-E
that regulate its binding to SUMO-2 chains. Using GPS-SUMO, a bioinformatics tool, we
identified five other putative SIMs in the tail domain of CENP-E.
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Figure 4.2. Diagram showing the putative SIM motifs in the tail domain of CENP-E using the software GPSSUMO.

In order to investigate if these putative SIMs are important for binding to SUMO-2 chains,
three of the four hydrophobic core residues within SIM2 and SIM4 were simultaneously mutated
to alanine using site directed mutagenesis. As a preliminary experiment, I tested if these mutants
had defect in localizing to the kinetochores similar to SIM3 mutant. HeLa cells were transfected
with either WT or one of the SIM mutants (SIM2, 3 or 4) of FLAG-CENP-E (tail domain). 48
hours after transfection, cells were fixed with 3.5% paraformaldehyde for 7 min and permeabilized
with 0.2% Triton-X-100 for 20 min. The cells were stained with anti-FLAG and anti-CREST
primary antibodies for one hour. After washing the coverslips, secondary antibodies were added
and mounted on glass slides. The slides were observed using Olympus inverted IX81 fluorescence
microscope. Similar to WT FLAG-CENP-E transfected cells, both SIM2 and SIM4 mutants of
FLAG-CENP-E co-localized with CREST, suggesting that each of the two putative SIMs is not
required for CENP-E kinetochore localization. Consistent with the published data, SIM3 mutant
of FLAG-CENP-E did not co-localize with CREST (Zhang et al., 2008)(Figure 4.3).
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Figure 4.3. SIM 2 and SIM 4 motifs of CENP-E are not required for its kinetochore localization. HeLa cells
were transfected with either WT or one of the SIM mutants of the tail domain of CENP-E as indicated. 48 hours after
transfection, cells were fixed and an immunofluorescence was performed using anti-FLAG and anti-CREST
antibodies.

Further, I would test if the other SIM mutants, SIM1, SIM5 and SIM6 have defect in kinetochore
localization by performing similar experiments as in Figure 4.3.
Both RNF4 and ZMYM2 mutants where only a single SIM is mutated have decreased
binding capacities to polymeric SUMO-2 chains compared to their respective WTs. However,
when more than one SIM motifs are mutated, the defect in binding to poly-SUMO-2 chains is more
pronounced (Aguilar-Martinez et al., 2015; Xu et al., 2014). Therefore, it would be interesting to

101

test if combinations of the several SIM mutants (simultaneous mutation of SIM2 and SIM4 and
likewise) in CENP-E has defect in its localization to the kinetochores because of deficiency in
binding to polymeric SUMO-2 chains.
ZMYM2 (a multi-SIM protein) binds better to multiSUMOylated protein rather than to
polySUMOylated protein (Aguilar-Martinez et al., 2015) (Figure 4.4). PolySUMOylation is a
linear chain of SUMO whereas, multiSUMOylation is either mono SUMO moieties on the same
protein or on different proteins in a complex. Based on the results from Figure 3.4 in Chapter 3,
Nuf2-3xSUMO-2 (a linear chain of SUMO-2) can rescue chromosome segregation defects and
CENP-E mislocalization better than Nuf2, in cells with overexpression of SENP2. However, the
rescue is only partial. One reason as mentioned before could be due to the orientation of the
SUMO-2 chains. In this case, we assume that CENP-E through its SIM/s binds to linear poly
SUMO-2 chains. However, there is a possibility that CENP-E binds with better affinity to
multiSUMOylated protein (Nuf2) than with polySUMOylated protein (Nuf2) similar to ZMYM2
(Aguilar-Martinez et al., 2015).

Figure 4.4. Diagram showing interaction between a multi-SIM protein and a substrate which has SUMO chains
from a single lysine residue (polySUMOylation) versus a substrate which has single SUMO moeities at multiple
lysine residues (multiSUMOylation).

In order to test this, a fusion construct GST-Nuf2-COMP-SUMO-2 can be utilized. The
linker region COMP corresponds to the coiled coil pentamerization domain of Cartilage
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Oligomeric Matrix Protein (Aguilar-Martinez et al., 2015) (Figure 4.5). An in vitro binding assay
can be performed to check if CENP-E (tail domain) binds to GST-Nuf2-COMP-SUMO-2 with
better affinity than to GST-Nuf2-3xSUMO-2. If this is true, then we can test if FLAG-Nuf2COMP-SUMO-2 can rescue CENP-E mislocalization caused by SENP2 overexpression better
than FLAG-Nuf2-SUMO-2.

GST

Nuf2

GST

Nuf2

Figure
4.5.
Cartoon
showing
GST-Nuf2-COMP-SUMO-2.

S-2
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the

two

fusions

S-2

S-2

S-2
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GST-Nuf2-3xSUMO-2

and

4.3 Will longer chains of SUMO-2 fused to Nuf2 boost the rescue of mitotic
defects caused by SENP2 overexpression?
RNF4 binds SUMO-2/3 chains through its four SIMs found in the N-terminal and leads to
ubiquitination of polymeric SUMO-2/3 modified substrates and proteasome-mediated
degradation. Interestingly, it is found that RNF4 interacts with SUMO-2 chains with at least three
moieties or higher (Xu et al., 2014). A large number of SUMO targets are being identified rapidly
and as mentioned above SUMO modification of many of these proteins regulate their localization,
function or activity. Although it is known that polymeric SUMO-2/3 chains are conjugated to many
substrates in vivo, how these chains regulate the protein function or activity is largely unknown.
Similar to a single SUMO moiety conjugated to a substrate (target protein) can serve as a hindrance
for its interaction with its partner (interacting protein), one can imagine that a polymeric SUMO
chain can have the same effect as shown in the cartoon below in Figure 4.6A. In certain other
cases, a polymeric SUMO chain can recruit proteins containing a SIM Figure 4.6B.
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Figure 4.6. Diagram showing the interaction between a poly SUMO-modified protein and its interacting
partner. (A) Sometimes, the interaction between two proteins is disrupted when the poly-SUMO chains on one protein
blocks the interacting motif on it. (B) In certain other cases, poly-SUMO chains can enhance the interaction with its
binding partner because of the presence of SUMO Interacting Motif (SIM).

The latter is consistent with the data that CENP-E binds to Nuf2-3xSUMO-2 with better
affinity than with Nuf2 (Zhang et al., 2008). Besides, an earlier study in budding yeast showed that
a protein ZIP1 interacts with chains of Smt3 (Cheng et al., 2006a). ZIP1, a part of the synaptonemal
complex, is essential for meiotic chromosome synapsis. However, only a single SIM is recorded
on ZIP1 so far, as against to multiple SIMs in close proximity, as one would expect.
In the study in Chapter 3, I have demonstrated that trimeric SUMO-2 chain fused to Nuf2
acts as the minimum signal for the recruitment of CENP-E to the kinetochores. However, it would
be interesting to test if a longer polymeric chain of Nuf2 can serve as a better signal for localizing
CENP-E to the kinetochores during overexpression of SENP2. In order to investigate this
possibility, fusion constructs with either four or five SUMO-2 moieties fused to the C-terminus of
Nuf2 was created. Below is the diagram of the constructs (Figure 4.7A). These constructs were
confirmed by restriction digestion as shown below (Figure 4.7B and C).
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B

C

Figure 4.7. Construction of FLAG-Nuf2-4xSUMO-2 and FLAG-Nuf2-5xSUMO-2 vectors. (A) Diagram showing
the FLAG-Nuf2 construct with either four or five SUMO moieties fused to its C-terminus. (B and C) Conformation
of the vectors using restriction digestion to cleave the four and five SUMO moieties.

After confirming these constructs for expression of the expected proteins, HeLa cells will
be co-transfected with Myc-SENP2 and one of the four constructs, including FLAG-Nuf2
(control), FLAG-Nuf2-3xSUMO-2 (positive control), FLAG-Nuf2-4xSUMO-2, and FLAG-Nuf25xSUMO-2. Similar to experiments performed in Figures 3.2, 3.4 and 3.5 in Chapter 3, 48 hours
after transfection cells will be fixed and stained with anti-FLAG and anti-Myc. The transfected
mitotic cells in different phases of cell cycle will be counted and quantified using
immunofluorescence microscopy. A second set of transfected cells will be stained with antiCENP-E and anti-Myc antibodies. Transfected mitotic cells will then be analyzed by
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immunofluorescence microcopy for chromosome alignment to metaphase plates and CENP-E
localization to kinetochores. These results will address the question whether the longer polymeric
SUMO-2 chain modification of Nuf2 can further enhance CENP-E targeting to kinetochores and
chromosome congression in cells with inhibition of SUMOylation.
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APPENDIX A
Table A.1 PCR primers for subcloning human SUMO-1
SUMO-1

Size
(aa)

A

38

B

42

C

38

B1

21

B2

20

B3

21

B31

12

B32

12

B33

12

B34

13

B35

12

B36

10

Forward Primers

Reverse Primers

GCGGATCCATGTCTGACCAG
GAG
GCGGATCCGGACAGGATAGC
AGT
CGCGGATCCAATTCACTCAG
GTTT
CGGGATCCGGACAGGATAGC
AG
CGGGATCCAAAATGACAACA
CATCTC
CGGGATCCGAATCATACTGT
CAAAGA
CGGGATCCGAATCATACTGT
CAAAGA
CGGGATCCTACTGTCAAAGA
CAGGGT
CGGGATCCCAAAGACAGGGT
GTTC
CGGGATCCCAGGGTGTTCCA
AT
CGGGATCCCCAATGAATTCA
CTCA
CGGGATCCCCAATGAATTCA
CTC

CGCCTCGAGCACTTTGAAGTG
AATCTC
GCCTCGAGCTGACCCTCAAAG
AG
GCCTCGAGACCCCCCGTTTGT
T
CGCCTCGAGTTTGAGTTTCTT
GAGATG
GCCTCGAGTGGAACACCCTGT
CTT
GCCTCGAGCTGACCCTCAAAG
AG
CGCCTCGAGATTCATTGGAAC
ACC
GCCTCGAGGAGTGAATTCATT
GGAAC
CGCCTCGAGAAACCTGAGTG
AATTC
CGCCTCGAGCTCAAAGAGAA
ACCTG
GCCTCGAGCTGACCCTCAAAG
AG
CGCCTCGAGCTCAAAGAGAA
ACCT

Table A.2 PCR primers for subcloning human SUMO-2
SUMO-2

Size
(aa)

A

40

B

38

C

43

C1

22

C2

21

Forward Primers

Reverse Primers

GCGGATCCATGGCCGACGAA
AAG
GCGGATCCGATGGTTCTGTG
GTG
GCGGATCCCAGGGATTGTCA
ATG
CGGGATCCCAGGGATTGTCA
ATG
CGGGATCCTTTGACGGGCAA
C

CGCCTCGAGAAGTGGTGTATG
CCTC
CGCCTCGAGGTCAAATCGGA
ATCT
CGCTCGAGACCTCCCGTCTGC
TG
GCCTCGAGTGTGTCTGTTTCA
TTGATTG
GCCTCGAGATCTTCATCCTCC
ATTTC
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C3

21

C11

13

C12

12

C13

12

C14

12

C15

13

C16

10

CGGGATCCCCTGCACAGTTG
GCCTCGAGACCTCCCGTCTGC
G
CGGGATCCCAGGGATTGTCA GCCTCGAGGTCAAATCGGAAT
ATG
CT
CGGGATCCTCAATGAGGCAG GCCTCGAGTTGCCCGTCAAAT
ATC
C
CGGGATCCAGGCAGATCAGA
GCCTCGAGGATTGGTTGCCC
TTC
CGGGATCCATCAGATTCCGA GCCTCGAGTTCATTGATTGGT
TTTG
TGC
CGGGATCCTTCCGATTTGAC CGCCTCGAGTGTGTCTGTTTC
GG
ATTG
CGGGATCCATCAGATTCCGA
GCCTCGAGGATTGGTTGCCC
TTT

Table A.3 PCR primers for site-directed mutagenesis to generate nonconjugatable SUMO-2/3 mutants
Forward Primers
CAGCAGACGGCAGCTTAGGGATCCACC

Reverse Primers
GGTGGATCCCTAAGCTGCCGTCTGCT
G

Table A.4 Plasmids used in Chapter 2
Clone IDs

Gene Names

HsCD00045456

α-Actinin 4

HsCD00000031

α-Enolase 1

HsCD00043134

RhoGDI1

HsCD00399275

PML

HsCD00044258

MIF

HsCD00044250

Gelsolin

HsCD00434238

Vimentin

Sources
DNASU, Tempe, AZ,
USA
DNASU, Tempe, AZ,
USA
DNASU, Tempe, AZ,
USA
DNASU, Tempe, AZ,
USA
DNASU, Tempe, AZ,
USA
DNASU, Tempe, AZ,
USA
DNASU, Tempe, AZ,
USA
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Table A.5 Peptides used in Chapter 2 for SUMO-1-ePIPE and
SUMO-2/3-ePIPE
Peptides
SUMO-1 Control
SUMO-1 Epitope (B34)
SUMO-2 Control
SUMO-2 Epitope (C14)

Applications
SUMO-1-ePIPE
SUMO-1-ePIPE
SUMO-2/3-ePIPE
SUMO-2/3-ePIPE

Sequences
49-ESYCQRQGVPMN-60
55-QGVPMNSLRFLFE-67
51-QGLSVRQIRFRFD-63
58-IRFRFDGQPINE-69

Table A.6 Antibodies used in Chapter 2
Antibodies

Species

Sources

Applicati
ons

SUMO-1 (21C7)

Mouse

Zhang Lab / Invitrogen / DSHB

WB / IF

SUMO-2/3 (8A2)

Mouse

Zhang Lab / Abcam / DSHB

WB / IF

α-Tubulin
(DM1A)

Mouse

Ubc9

Rabbit

N-Cadherin

Mouse

GST

Mouse

BD Biosciences, Franklin Lakes, NJ,
USA
Santa Cruz, Santa Cruz, CA, USA

PML

Rabbit

Santa Cruz, Santa Cruz, CA, USA

WB / IF

MIF
FLAG (M2)
RanGAP1

Rabbit
Mouse
Rabbit

WB
WB
IF

hnRNP U (3G6)

Mouse

WB

1:1000

α-Enolase
Pyruvate Kinase
M2

Rabbit

Invitrogen, Carlsbad, CA, USA
Sigma -Aldrich, St. Louis, MO, USA
Dasso Laboratory, NIH
Dreyfuss Lab (HHMI, U of Penn) /
Abcam
Abcam, Cambridge, MA, USA

1:10,00
0
1:150
1:500 /
1:50
1:2000
1:800
1:2000

WB

1:5000

Rabbit

GeneTex, Irvine, CA, USA

WB

1:1000

Sigma -Aldrich, St. Louis, MO, USA
Abcam, Cambridge, MA, USA

Dilutio
ns
1:1000
/ 1:300
1:800 /
1:300

WB

1:5000

WB

1:300

WB
WB
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APPENDIX B
Table B.1 Primers used for pFLAG-Nuf2 constructs in Chapter 3
Plasmid
pFLAG-Nuf2

Forward primer
CCATCGATAATGGAAACT
TTGTCTTTCCCCAG

pFLAG-Nuf2
CCATCGATAATGGAAACT
(mutated stop
TTGTCTTTCCCCAG
codon)
3xSUMO-1 to
CGAGGATCCATGTCTGAC
generate pFLAGCAGGAGGC
Nuf2-3xSUMO-1
pFLAG-Nuf2CCATCGATAATGGAAACT
SUMO-2
TTGTCTTTCCCCAG
3xSUMO-2 to
CGGGATCCATGGCCGACG
generate pFLAGAAAAGCCCAAG
Nuf2-3xSUMO-2
Ubc9 to generate
TGGGATCCATAATGTCGG
pFLAG-Nuf2-Ubc9
GGATCGC
(WT)
pGEX6p-1
GACCCCGGGAATGGAAA
GST-Nuf2
CTTTGT
pGEX6p-1
GACCCCGGGAATGGAAA
GST-Nuf2CTTTGT
3xSUMO-2

Reverse primer
GCGGATCCTCAGGTTGACATTT
TGAACATCTTCC
GCGGATCCCCAGGTTGACATTT
TGAACATCTTCC
TAATTTTAACCCGGGAAGCTCG
AGTCAACC
GCTCTAGAGAATTCAGCTCACG
T
TCCCCCGGGCCCTCTAGATGCA
TGCTCGAG
ATTCCCCGGGTTAAGACGGAGC
AAACTTCTT
GGCGTGTCGACTCAGGTTGACA
TT
CGCACTGTCGACATGCTCGAGC
TA

Table B.2 Primers used for mutagenesis in Chapter 3
Plasmid
pFLAG-Nuf22xSUMO-2
pFLAG-Nuf2-Ubc9
(C93A)
Nuf2 K41R
Nuf2 K165R
Nuf2 K402R
Nuf2 K447R

Forward primer
CAGACGTGAGCTCTGCAG
AAGACT
TCGGGGACAGTGGCC
CTGTCCATCTTAGAG
CTTTATCCAAATCCAAGGCC
TGAAGTCTTGCAC
GAGGCATTAATGAGACTG
GAGAGACTTGATTC
CAAGAAATCCAAAAAATTA
GACTTGGAATTCAACAAC
GAGGACTCCTATGCTAGGAT
AGATGAGAAGACAG

Reverse primer
AGTCTTCTGCAGAGCTCA
CGTCTG
CTCTAAGATGGACAG
GGCCACTGTCCCCGA
GTGCAAGACTTCAGGCCTTG
GATTTGGATAAAG
GAATCAAGTCTCTCCAGTCT
CATTAATGCCTC
GTTGTTGAATTCCAAGTCTA
ATTTTTTGGATTTCTTG
CTGTCTTCTCATCTATCCTAG
CATAGGAGTCCTC
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Table B.3 Antibodies used in Chapter 3
Dilution
s
1:1000 /
1:200
1:800 /
1:300

Antibodies

Species

Sources

Applications

Nuf2

Rabbit

Bethyl Laboratories,
Montgomery, TX, USA

WB / IF

SUMO-2/3 (8A2)

Mouse

Zhang Lab / Abcam / DSHB

WB / IF

α-Tubulin
(DM1A)

Mouse

Sigma -Aldrich, St. Louis, MO,
USA

WB

1:5000

Ubc9

Rabbit

GeneTex, Irvine, CA, USA

WB

1:5000

Myc

Rabbit

IF

1:300

FLAG

Rabbit

IF

1:200

GST

Mouse

WB

1:150

CREST

Human

IF

1:10000

CENP-E

Mouse

IF

1:500

FLAG (M2)

Mouse

WB

1:800

RanGAP1

Rabbit

IF

1:2000

Cell Signaling, Danvers, MA,
USA
Bethyl Laboratories,
Montgomery, TX, USA
Santa Cruz, Santa Cruz, CA,
USA
Brinkley lab, Baylor College of
Medicine
Yen lab, Fox Chase Cancer
Center
Sigma -Aldrich, St. Louis, MO,
USA
Dasso lab, NIH

Table B.4 siRNAs
Name
Control siRNA
RNAi 1
RNAi 2
RNAi

Targeting region (nt)
Non-targeting
Nuf2 (397-415)
Nuf2 (241-259)
Ubc9 (86-104)

siRNA sense sequence
UUCUCCGAACGUGUCACGU
GCAUGCCGUGAAACGUAUA
GGCUUCUUACCAUUCAGCA
CAAAAAATCCCGATGGCAC
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Roles of SUMOylation in cancer metastasis and mitotic progression has been elucidated in
this thesis. This vital and dynamic post-translational modification has been known to be
dysregulated in several kinds of cancer. Global SUMO-2/3 conjugation is upregulated in a mouse
metastatic breast cancer cell line, 66cl4, compared to a non-metastatic cell line 168FARN from
the same genetic background. In order to identify the SUMO-2/3 substrates, SILAC labeled lysates
from the two cell lines were immunopurified using SUMO-2/3 monoclonal antibodies. By using
SUMO-2/3 epitope peptide elution (SUMO-2/3-ePIPE) and quantitative mass spectrometry, 66
SUMO-2/3 targets were identified, of which 15 targets are upregulated/downregulated in 66cl4
compared to 168FARN and 45 substrates are linked to cancer. About ten of these substrates were
validated using in vitro and in vivo SUMOylation assays. Further, overexpression of GFP-tagged
SUMO-2/3 in 168FARN cells increased in 3D cell migration compared to control cells
overexpressing GFP. These results clearly show a link between SUMO and cancer metastasis. As
we know, uncontrolled cell division is a hallmark of cancer and therefore I focused on
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understanding the role of SUMO-2/3 modification in regulating cell cycle progression through
mitosis in the second half of my thesis. Inhibition of global SUMOylation resulted in a
prometaphase arrest and mislocalization of CENP-E from kinetochores. CENP-E has a SUMO
interacting motif required for its kinetochore localization. We found that these mitotic defects in
cells with inhibition of SUMOylation can be rescued by overexpressing Nuf2-SUMO2-SUMO2SUMO2 fusion proteins, but not by Nuf2-SUMO2, Nuf2-SUMO2-SUMO2, and Nuf2-SUMO1SUMO1-SUMO1 fusion proteins. Notably, we used these Nuf2 fusion proteins to mimic the
various types of Nuf2 SUMOylation at kinetochores. We also demonstrated that Nuf2 is critical
for CENP-E localization to kinetochores and also modified by polymeric SUMO chains both in
vitro and in vivo. Importantly, we show that Nuf2-SUMO2-SUMO2-SUMO2 fusion protein has
better binding affinity to CENP-E compared to Nuf2. These results suggest that trimeric SUMO2/3 modification of Nuf2 represent the minimum and distinct signal for targeting CENP-E to
kinetochores and mitotic progression in mammalian cells.
Supplementary dataset 1 is included along with this thesis.
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